CONTROLLED RELEASE INHALABLE POLYMERIC MICROSPHERES FOR TREATMENT OF PULMONARY HYPERTENSION by APARNA SAIGAL
CONTROLLED RELEASE INHALABLE  
POLYMERIC MICROSPHERES  






B.Pharm. (Hons.), University of Delhi 
 
A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF 
PHILOSOPHY 
DEPARTMENT OF PHARMACY 
 






It would not have been possible to write this doctoral thesis without the 
help and support of the kind people around me, to only some of whom it is 
possible to give particular mention here. 
Above all, I would like to thank Jaspreet for his personal support and 
great patience at all times. My parents and sister have given me their 
unequivocal support throughout, as always, for which my mere expression of 
thanks likewise does not suffice. 
This thesis would not have been possible without the help, support and 
patience of my principal supervisor, A/P Chan Sui Yung. Her input and 
encouragement at every stage of PhD have been a great driving force. I am 
also deeply grateful to my supervisors Dr Ng Wai Kiong and Prof Reginald 
Tan of A*STAR’s Institute of Chemical and Engineering Sciences (ICES), for 
their valuable suggestions, insights and constant encouragement which urged 
me to think deeper and understand the scientific reason behind formulation 
concepts.  
I would like to thank the head and staff of Department of Pharmacy, 
NUS for providing me the NUS-Industrial Postgraduate Programme 
scholarship and also for the constant support of the laboratory support staff 
and administrative staff, without whom this PhD would not have been 
possible. 
I also want to extend my gratitude to the staff at A*STAR, ICES, 
namely, Dr Desmond Heng, Dr Parijat Kanujia, Dr Sendhil Poornachary, Mr 
Hu Jun, Mr Kwek Jin Wang, Mr Leonard Chia, Mr Ng Junwei, Ms Lee Sie 
ii 
 
Huey, Mr Lim Ming Wei, Mr Frederick Toh, Ms Tan Li Teng, Ms Agnes 
Phua and Mr Xavier Heng for all their help and support. 
I am obliged to Dr Kang Lifeng for allowing me to use his laboratory 
to carry out the cell work and his PhD student Ms Pan Jing for helping me 
with those experiments. I also thank my laboratory mates at NUS Dr Cheong 
Han Hui, Dr Li Fang and Dr Perry Lim for their advice and assistance. 
Lastly, I thank my friends at ICES, NUS and at home in India for the 















TABLE OF CONTENTS 
         Page 
Acknowledgements       i 
Table of Contents       iii 
Summary        viii 
List of Tables        xi  
List of Figures        xii 
List of Abbreviations       xv 
List of Publications       xvii 
List of Awards       xix 
Chapter 1 Introduction 
1.1 Lungs as a route of drug administration   1 
1.2 History and development of inhaled medicine   3 
1.3 Dry powder inhalers      6 
1.4 Spray drying       7 
1.5 Pulmonary hypertension     10 
1.5.1 Introduction      10  
1.5.2 Current treatment options    11 
1.5.2.1 Parenteral formulations   14 
1.5.2.2 Oral formulations    16 
1.5.2.3 Inhaled formulations    17 
1.5.2.4 Combination treatments   19 
1.5.3 Concerns with available treatment   19 
1.5.3.1 Intravenous infusions    19 
1.5.3.2 Oral formulations    20 
iv 
 
1.6 Prostanoids and calcium channel blockers for   21 
pulmonary hypertension 
1.6.1 Prostanoid: Iloprost    21 
1.6.2 Calcium channel blocker: Nifedipine  22 
1.7 Controlled release inhalation systems    23 
1.8 In vitro testing of inhalation controlled release formulations 25 
1.9 Hypothesis and objectives     27 
Chapter 2 Materials and methods  
2.1. Materials        29  
2.2. Development of controlled release inhalable    30 
polymeric microspheres for treatment of pulmonary  
hypertension 
2.2.1. Formulation of microspheres by spray drying 30  
2.2.2. Physicochemical characterization of microspheres 31 
2.2.2.1 Particle size analysis    31 
2.2.2.2 Particle morphology    31 
2.2.2.3 Drug crystallinity    32 
2.2.2.4 Thermal analysis    32  
2.2.2.5 Drug polymer interaction   32 
2.2.3. Drug distribution within microspheres  32  
2.2.4. Drug encapsulation efficiency   33 
2.2.5. In vitro drug release profile    34 
2.2.6. In vitro microsphere aerosolization   34 
2.2.7. Statistical analysis     35 
2.3. Enhancement of the formulated microspheres   35 
2.3.1 Formulation of microspheres by spray drying 35 
2.3.1.1 Chitosan-EtOH microspheres (Ch-N-EH) 35 
2.3.1.2 PVA-EA microspheres (P-N-EA)  36 
2.3.2 Physicochemical characterization of microspheres 37 
2.3.2.1 Particle size analysis    37 
2.3.2.2 Morphology     37 
v 
 
2.3.2.3 Surface mapping    37 
2.3.2.4 Drug crystallinity    38 
2.3.2.5 Thermal analysis    38 
2.3.2.6 Drug polymer interaction   38  
2.3.3 Ethyl acetate determination in P-N-EA  38 
 microspheres 
2.3.4 Drug distribution within microspheres  39 
2.3.5 In vitro drug release profile    39 
2.3.6 Rate order of drug release    39 
2.3.7 Microsphere microstructure    40 
2.3.8 In vitro microsphere aerosolization   40 
2.3.9 Cytotoxicity screening    40 
2.3.9.1 PVA polymer     41 
2.3.9.2 Chitosan polymer    42  
2.3.10 Microsphere lung residence time   42 
2.3.11 Accelerated stability study    43 
2.3.12 Statistical analysis     43 
2.4. Comparison of different dissolution apparatus   43 
for inhalation formulations of water insoluble drug  
2.4.1 USP Type II apparatus    43 
2.4.2 Franz diffusion cell     44 
2.4.3 USP Type IV apparatus    44 
Chapter 3 Development of controlled release inhalable polymeric 
microspheres for treatment of pulmonary hypertension 
3.1. Overview       46 
3.2. Results        47 
3.2.1. Physicochemical characterization of microspheres 47 
3.2.1.1 Particle size analysis    47 
3.2.1.2 Morphology     48 
3.2.1.3 Drug crystallinity    49 
3.2.1.4 Thermal analysis    50 
vi 
 
3.2.1.5 Drug polymer interaction   51 
3.2.2. Drug distribution within microspheres  52 
3.2.3. Drug encapsulation efficiency   53 
3.2.4. In vitro drug release profile    54 
3.2.5. In vitro microsphere aerosolization   55  
3.3. Discussion       57  
3.4. Summary       59  
Chapter 4 Enhancement of the formulated microspheres  
4.1. Overview       60 
4.2. Results        61 
4.2.1. Physicochemical characterization of microspheres  63 
4.2.1.1 Particle size analysis    63 
4.2.1.2 Morphology     63 
4.2.1.3 Surface mapping    65  
4.2.1.4 Drug crystallinity    66 
4.2.1.5 Thermal analysis    67 
4.2.1.6 Drug polymer interaction   67 
4.2.2. Ethyl acetate determination in P-N-EA   69  
microspheres 
4.2.3. Drug distribution within microspheres  70 
4.2.4. In vitro drug release profile    71 
4.2.5. Rate order of drug release    71 
4.2.6. Microsphere microstructure    72 
4.2.7. In vitro microsphere aerosolization   73 
4.2.8. Cytotoxicity screening    76 
4.2.7.1 PVA polymer     76 
4.2.7.2 Chitosan polymer    77 
4.2.9. Microsphere lung residence time   77 
4.2.10. Accelerated stability study    79 
4.2.9.1 Morphology     79 
vii 
 
4.2.9.2 Drug crystallinity    82 
4.2.9.3 Aerosolization efficiency    84 
4.3. Discussion       88  
4.4. Summary       90  
Chapter 5 Comparison of different dissolution apparatus for inhalation 
formulations of water insoluble drug  
5.1 Overview       91 
5.2 Results         92 
5.2.1  USP Type II apparatus (Paddle)   92 
5.2.2 Franz diffusion cell     93 
5.2.3 USP Type IV apparatus (Flow through)  94  
5.3 Discussion       97  
5.4 Summary       98  
Chapter 6 Conclusions and future directions 
6.1 Conclusions       100 
6.2 Future directions      102 




Pulmonary hypertension (PAH) is a chronic ailment of the lungs, 
exhibiting elevated arterial pressure and vascular resistance; with a mean 
arterial pressure above 25 mmHg at rest and above 30 mmHg during exercise. 
It is associated with poor prognosis, and its prevalence is estimated to be 15 
cases per one million adults.  Among the various treatment options available 
for PAH, the prostanoid class of drugs has proven to be the most effective. 
They act by dilating systemic and pulmonary arterial vascular beds and, with 
sustained long-term usage, altering pulmonary remodelling. Presently 
prostanoids are administered as IV infusions or inhalation solutions. Despite 
their clinical effectiveness, prostanoids have short half-lives requiring frequent 
administration, and thus do not appeal to patients. 
In this thesis, controlled release polymeric microspheres were 
developed which reside in the lungs over a prolonged period of time, release 
the drug slowly reducing the number of doses to be administered to the 
patient. Nifedipine was used as the model drug in this thesis because of its 
similarity to prostanoid Iloprost in terms of logP and molecular weight. 
Nifedipine belongs to the class of calcium channel blockers that are also used 
for hypertension treatment. Polymeric microspheres were first formulated 
using polyvinyl alcohol (PVA) polymer, with varying polymer:drug ratio. For 
these microspheres, ethanol-water cosolvent was used and microspheres were 
formulated by spray drying. The microspheres were then characterized for 
their physicochemical properties. A burst release was observed in all cases 
with least in microspheres with 90:10 polymer-drug ratio. In chapter 3, three 
different ratios of PVA and nifedipine were studied and 90:10 PVA:nifedipine 
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was identified as suitable to control drug release. Then the cosolvent was 
changed with ethanol replacing ethyl acetate. The emulsion system slowed the 
drug release when compared to the solution system. Then PVA replaced by 
chitosan, a polymer with a higher molecular weight, to control the drug 
release. Finally, chitosan with ethanol – water cosolvent was used to formulate 
microspheres. The particle size was significantly reduced for these 
microspheres resulting in good aerosol performance. The chitosan 
microspheres also showed a significant reduction in drug release. Accelerated 
stability study was performed on the three batches of microspheres which 
showed that the aerosol properties remained unchanged when stored under 
controlled conditions of temperature and humidity even after 6 months. 
Microspheres were also tested for their residence time within the lungs in the 
presence of macrophages which showed that at 24 h, few microspheres were 
taken up by the macrophages and most resided in the lungs to release the drug. 
Currently, there are no standardised methods to determine drug release 
from inhalation formulations. Lack of pharmacopoeial methods has led to a 
plethora of equipments and techniques being used by inhalation researchers. In 
the last part of this thesis, three different dissolution apparatus; USP Type II 
(paddle type), Franz vertical diffusion cell and USP Type IV (flow through) in 
an open loop setup were studied to determine the suitability of equipment for 
the formulations developed. After weighing the pros and cons of the 
equipments it was concluded that flow through apparatus in an open loop 
setup was most appropriate for inhalation powders with water insoluble drugs 
which intend to extend the drug release. Open-loop setup allows sink 
conditions to be maintained, making it a suitable technique to study the 
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dissolution kinetics of poorly water-soluble drugs. Flexible, permitting 
changes to be  made even within a test run, of temperature, flow rate, 
viscosity, surfactant concentration and pH. Drug particles collected on the 
filter experience essentially the same intensity of solvent flow. The output 
sampling volume can be altered by the flow rate of the solvent, can mimic 
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1.1 Lungs as a route of drug administration 
 The human lungs are the site for gaseous exchange and efficient air 
filtration. Its anatomy, comprising of the two-layered thick alveolar capillary 
membrane along with physiological mechanisms, controlling airway function 
and pulmonary hemodynamics make the pulmonary route an ideal pathway for 
external/internal exchange. To understand the importance of lungs as a means 
for delivering drugs, it is imperative to learn the mechanisms of particle 
deposition within and absorption at this site.  Particle deposition can take place 
by four mechanisms of inertial impaction, sedimentation, interception and 
diffusion with sedimentation and inertial impaction making the major 
contribution. Knowledge of the lung structure helps to understand the 
opportunities and obstacles for aerosolized drug delivery. Based on the 
pathway of air flow into and out of the lung, the lung has been 
compartmentalised into two zones; the conducting zone and the respiratory 
zone (Figure 1.1) [1, 2]. 
 The conducting zone of the lung begins with the trachea which then 
bifurcates into bronchi entering the left and right lung lobes. These bronchi 
continue to subdivide within the lungs into progressively smaller bronchi and 
bronchioles. Main function of this conducting zone is to move air into and out 
of the lungs with each breath taken. The respiratory zone contains the 
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respiratory bronchioles which subdivide into alveolar ducts and finally alveolar 
sacs. The respiratory zone is responsible for gaseous exchange in the lungs [3].  
 
 
Figure 1.1 Lung morphology; conducting zone (trachea-terminal bronchioles) 
and respiratory zone (respiratory bronchioles-alveolar sacs) 
 
 
 Drugs can be administered as aerosols which are airborne suspensions 
of fine particles. These particles can be either liquid droplets or solids that 
remain suspended for long enough to penetrate deep into the lungs. The 





Advantages of pulmonary route of administration 
 1.  Rapid drug absorption across broncho-pulmonary mucosal membrane 
 2.  Faster onset of drug action 
 3.  Systemic side effects greatly reduced [4] 
 4.  Increased drug potency 
 5.  Reduced doses to be administered due to drug targeting at site of action 
[5] 
 6.  Avoidance of hepatic first pass effect and other variables associated 
with the GI tract, such as pH, gastric emptying time 
 7.  Direct access to target site i.e. lungs 
 8.  Painless administration 
  
Table 1.1 Advantages of pulmonary route of administration  
 
However, this route also has its own drawbacks as highlighted in Table 1.2. 
Limitations of pulmonary route of administration 
 1.  Decreased therapeutic effect of some drugs e.g. some corticosteroids [6, 
7] 
 2.  Patients with acute condition may be able to tolerate oral or 
intravenously administered drugs better e.g. corticosteroids for asthma 
[6, 7] 
 3.  Drugs not deposited within lungs are orally ingested which can lead to 
systemic side effects 
 4.  Most drugs have low bioavailability because of poor absorption or 
inactivation by lung enzymes 
 
Table 1.2 Limitations of pulmonary route of administration 
 
 The tables highlight that despite the limitations of the pulmonary route, 
it has proved to be very effective in treating conditions of the lungs and even 
some systemic conditions. 
1.2 History and development of inhaled medicine 
 Inhalation therapy was first described in Ayurvedic medicine more than 
4000 years ago [8]. To treat diseases of the throat and chest, leaves of Atropa 
belladonna containing atropine were smoked [9]. The Hindu physician, 
Charaka, also advised on the use of inhalation therapy to treat diseases of the 
4 
 
throat and chest. Spices, gum resins and fragrant wood were ground into 
powder and made into a paste. Thin tubes were smeared with paste and lighted. 
The smoke produced was then inhaled [9]. Bennet and co-workers also 
employed inhalation therapy for treatment of tuberculosis [9]. In 1810, 
Laennec and his research team recommended the inhalation of vapours 
released from a variety of sources like balsams, sulphur, aromatic plants for 
chest infections [9]. The first official inhaled drug to be approved by the US 
FDA was flunisolide given as a metered dose inhaler in 1984. Since then the 
interest in this area of drug delivery has increased manifold with about 40 
drugs approved by the US FDA (Figure 1.2 [10]). 
 
 
Figure 1.2 Cumulative number of inhalation products approved by FDA since 






 Aerosol drugs may be administered in the form of dry powder inhaler 
(DPI), metered dose inhaler (MDI), solution to be nebulized, or as a gas. Table 
1.3 lists the commercially available inhalation drugs approved by the FDA. 
 
S.No. Drug Formulation 
1. Acetylcysteine Inhalation solution 
2. Albuterol sulfate Metered aerosol 
3. Albuterol sulfate and Ipratropium 
bromide 
i. Inhalation solution 
ii. Metered aerosol 
4. Arformoterol tartarate Inhalation solution 
5. Aztreonam Inhalation solution 
6. Beclomethasone dipropionate Metered aerosol 
7. Budesonide i. Inhalation powder 
ii. Inhalation suspension 
8. Budesonide and formoterol fumarate 
dihydrate 
Metered spray for 
inhalation 
9. Ciclesonide Metered aerosol 
10. Cromyln sodium i. Metered aerosol 
ii. Inhalation solution 
11. Desflurane Inhalation liquid 
12. Enflurane Inhalation liquid 
13. Flunisolide Metered aerosol 
14. Fluticasone propionate i. Metered aerosol 
ii. Inhalation powder 
15. Fluticasone propionate and salmetorol 
xinafoate 
i. Metered aerosol 
ii. Inhalation powder 
16. Formeterol fumarate i. Inhalation powder 
ii. Inhalation solution 
17. Formeterol fumarate and mometasone Metered aerosol 
18. Iloprost Inhalation solution 
19. Ipratropium bromide i. Metered aerosol 
ii. Inhalation solution 
20. Isoflurane Inhalation liquid 
21. Levalbuterol hydrochloride Inhalation solution 
22. Levalbuterol tartarate Metered aerosol 
23. Mannitol Inhalation powder 
24. Metaproterenol sulfate Inhalation solution 
25. Methacholine chloride Inhalation solution 
26. Mometasone furoate Inhalation powder 
27. Nitric oxide Gas 
28. Pentamide isethionate Inhalation solution 
29. Pirbuterol acetate Metered aerosol 
30. Ribavarin Inhalation solution 
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31. Salmeterol xinafoate Inhalation powder 
32. Sevoflurane Inhalation liquid 
33. Tiotropium bromide monohydrate Inhalation powder 
34. Tobramycin Inhalation solution 
35. Treprostinil sodium Inhalation solution 
36. Triamcinolone acetonide Metered aerosol 
37. Xenone XE-133 Gas 
38. Zanamivir Inhalation powder 
39. Epinephrine Metered aerosol 
40. Sodium chloride Metered aerosol 
 
Table 1.3 Inhalation formulations approved by US FDA and available in 
market 
 
The above table shows the wide range of inhalation products that are available 
in the market, which has been growing steadily. 
1.3 Dry powder inhalers 
 Dry powder inhalers (DPI) were first developed in the 1960s and 1970s, 
as alternative devices to the then predominant propellant-driven metered dose 
inhaler (pMDI) products. First generation DPIs relied heavily on patients’ 
inspiratory flow for drug dispersion and hence lacked efficiency. Since then 
new technologies have been applied to this inhalation device system for 
example, use of energy for drug dispersion as seen in active DPIs. These 
deliver drugs in a more efficient manner when compared to the earlier device 
systems. DPIs consist of three key components; namely a powder formulation, 
a metering system and an aerosol dispersion mechanism. The powder 
formulation may contain either the drug alone or drug mixed with a filler or 
flow aid such as lactose [11]. As interest in pulmonary delivery systems 
increased, DPIs with matrix particles containing multiple components and 
newer ingredients like sugars as carrier particles were applied [12]. Metering 
system came as unit dose (capsules), multi-unit dose or reservoirs. The unit 
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dosing systems offer the advantage of uniformity of dosing and control of 
storage stability but because of multiple steps involved in administration, it is 
not patient friendly. A reservoir metering system allows convenient 
administration but challenges in uniform dosing and stability of product with 
storage forms a major drawback for this system.   
 Aerosol dispersion mechanisms are based on fine particle physics with 
different methods available to impart energy to powder beds for flow: 
pneumatic, mechanical (impact) and vibrational energy. 
1.4 Spray drying 
 For efficient drug delivery via pulmonary route, the aerosol droplets 
have to adhere to certain parameters of size and morphology. To reach the 
broncho-pulmonary mucosal surface, particles must be between 1-5 µm in 
diameter. Particles greater than 5 µm rarely reach the alveoli, where maximum 
absorption takes place and those below 0.5 µm are exhaled out without 
depositing in the lungs. Thus the ultimate aim of particle manufacturing 
techniques is to develop particles that will conform to the strict requirement 
and allow efficient, reproducible and reliable drug delivery to the lungs for 
treatment of respiratory conditions and/or systemic delivery. Particle 
engineering serves to optimize the size and surface area of the particles, as 
these determine regional deposition in the lungs as well as particle–particle 
interactions between the drug and the excipients, as well as particle–component 
interactions (such as the primary pack, actuator, etc.). Of the various particle 
manufacturing methods, spray drying and super critical technology are found 
to be effective for pulmonary particle design [13]. In this thesis spray drying 
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technology was applied for particle formulation and hence will be discussed in 
detail here.  
 Spray drying process converts a liquid feed into a dry particulate form, 
where the feed could be in solution, coarse or ultrafine suspension/slurry, 
colloidal dispersion (e.g., emulsions, liposomes, etc.), or a paste. During the 
spray drying procedure, the fluid feed is atomized to a spray form in contact 
with hot gaseous medium. This contact results in rapid evaporation of droplets 
to form the dried solid particles, eventually separated by a cyclone, 
electrostatic precipitator or bag filter (Illustrated in Figure 1.3). Atomization in 
a spray dryer may result from centrifugal (e.g. spinning disk), kinetic or 
pneumatic, electrostatic, high pressure, ultrasonic or effervescent methods.  
 
Figure 1.3 Schematic diagram of a spray dryer 
 Due to the versatility of the spray drying process which comprises a 
range of atomization, drying and separation techniques, it is a sought-after 
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procedure for many industrial applications. Parameters in the spray dryer can 
be adjusted to suit industrial requirements e.g. low temperature spray drying 
where drying air is maintained at low relative humidity for aqueous sample 
feeds; pulse combustion spray drying, where rapid solvent evaporation is 
achieved at low temperature using heat and acoustics; spray freeze drying [14-
20]; spray chilling; spray polycondensation [21]; spray reaction; spray dryer 
absorption and spray concentration [22]. Apart from aqueous feed, flammable 
organic solvents may also be safely processed in a spray dryer. The many 
proven adroit features of spray dryer has benefitted various industries such as 
pharmaceutical, chemical, food and environmental control. Vast literature is 
available to support the use of spray drying technique for the particle 
manufacture of inhalation drugs [23-33]; including heat sensitive and fragile 
proteins and peptides [25-30] and controlled release formulations (liposomes, 
polymeric, non-polymeric and cyclodextrins) [23, 32-34].   
Advantages of spray drying technology 
1. 1. Ability to manipulate and control particle size, size distribution, 
morphology and density 
2. 2.  3. At bulk powder level, it can control bulk density, flowability and 
dispersibility  
4. 3.  5. Suitable for heat-sensitive compounds due to rapid solvent evaporation 
and short particle residence time in the drying chamber 
6. 4.  7. Can be used for compounds with low aqueous solubility, due to the 
ability to spray dry organic solvents 
8. 5.  9. Good alternative to lyophilisation for fragile compounds like proteins 
and peptides, eliminating the post-processing steps  
 
Table 1.4 Advantages of spray drying for inhaled formulations 
 
Spray drying technology has a number of advantages with respect to pulmonary 




1.5 Pulmonary hypertension 
1.5.1 Introduction 
 Pulmonary hypertension (PAH) is an ailment of the lungs, exhibiting 
elevated arterial pressure and vascular resistance; with a mean arterial pressure 
above 25 mmHg at rest and above 30 mmHg during exercise [35]. It is a rare, 
progressive disease with poor prognosis. The most common form of pulmonary 
hypertension is one in which the disease is a result of other disorders, hence 
known as secondary pulmonary hypertension. In cases where it is not possible 
to incriminate an etiological cause to pulmonary hypertension, it is referred to 
as primary pulmonary hypertension [36]. The World Health Organisation 
classification of PAH is given in Table 1.5. 
Group I 
Pulmonary Arterial Hypertension (PAH) 
1. Idiopathic PAH (IPAH) 
2. Familial PAH (FPAH) 
3. Associative PAH (APAH) 
 Connective tissue disease 
 Congenital systemic-to-pulmonary shunts 
 Portal hypertension 
 HIV infection 
 Drugs and toxins 
 Other (thyroid disorders, glycogen storage disease, Gaucher's disease, 
hereditary hemorrhagic telangiectasia, haemoglobinopathies, 
myeloproliferative disorders, splenectomy) 
 Associated with significant venous or capillary involvement 
 Pulmonary veno-occlusive disease (PVOD) 
 Pulmonary capillary haemangiomatosis (PCH) 
4. Persistent pulmonary hypertension of the newborn (PPHN) 
Group II 
Pulmonary hypertension associated with left heart diseases 
Group III 
Pulmonary hypertension associated with respiratory diseases and / or 




Pulmonary hypertension due to chronic thrombotic and/or embolic disease 
Group V 
Miscellaneous group 
 e.g. sarcoidosis, histiocytosis X and lymphangiomatosis 
 
Table 1.5 The adapted WHO classification of Pulmonary Hypertension [37] 
 
 Two classes of endogenous substances are found in the lungs with 
antagonistic actions, namely, vasoconstrictors and vasodilators. In the 
pulmonary vasculature, the main vasodilator is prostacyclin (PGI2) and the 
main vasoconstrictor is thromboxane (TXA2). Prostacyclin, an arachidonic acid 
metabolite, causes vasodilation of the pulmonary arteries and systemic 
circulation by relaxing the smooth muscles and preventing platelet aggregation 
[38]. Thromboxane, produced from thromboxane synthase, on the other hand 
causes constriction of the smooth muscles and platelet aggregation [39]. Thus, 
PAH is a condition which arises mainly due to an imbalance between these two 
endogenous metabolites [40].  
 Normal pulmonary vasculature has a great capacity to dilate and 
accommodate high blood flow. In PAH patients, this capacity is diminished 
causing an increase in pulmonary artery pressure at rest which is further 
aggravated during exercise. The increased afterload leads to hypertrophy of the 
right ventricle. This condition of the heart worsens as the disease progresses, 
when finally the right heart is unable to maintain normal cardiac function in 
view of elevated resistance thus leading to decreased cardiac output [41]. 
1.5.2 Current treatment options 
 PAH is treated by various classes of drugs which compensate for the 
imbalance of the neurochemical mediators such as prostacyclin, nitric oxide 
and endothelin 1, which are required to maintain vascular tone in a healthy 
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individual. Prostanoids [42], endothelin receptor antagonists [43], calcium 
channel blockers [15], phosphodiesterase (PDE5) inhibitors [44-48] and 
inhaled nitric oxide [49] are administered to patients suffering from PAH. 
These treatments however, do not provide a cure for the disease but simply 



















































The treatment options classified according to the route of delivery are: 
i. Parenteral formulations 
ii. Oral formulations 
iii. Inhaled formulations 
Tables 1.7 and 1.8 list the current drugs available in the market for PAH; their 
formulations, actions, advantages and adverse effects. 
 
Table 1.7 Current drug therapy for pulmonary hypertension 
 
 
Drug Class Formulation Commercial 
Product 
Epoprostenol Prostanoid Continuous intravenous 
infusion 
Flolan® 















 intravenous solution 
Revatio® 
Nitric oxide - Inhaled INOmax 
Drug Mechanism of 
Action 
Advantages Adverse Drug 
Reactions 
Epoprostenol Activates PIP2 











Treprostinil Activates PIP2 
signal pathway to 
increase cAMP 
concentration 
Longer half-life, stable 
at room and higher 
temperature 




Iloprost Exact mechanism 
of action is 
unknown 
(a) Healed ulcers in 
digital areas of body 
(b) Improved exercise 
capacity, decrease in 
worsening of PAH 









Table 1.8 Mechanism of action, advantages and adverse reactions of drugs for 
PAH 
 
1.5.2.1 Parenteral formulations 
 There is a preponderance of intravenous infusions in the market for 
treatment of PAH which ensures a rapid treatment for emergency.  
 Epoprostenol is one of the principle drugs prescribed for PAH, given as 
an intravenous infusion. Epoprostenol belongs to the family of prostanoids, 
which causes vasodilation by activating the biochemical PIP2 signal 
transduction pathway thereby increasing the concentration of cAMP in the 
pulmonary vasculature. cAMP along with protein kinase A accelerates the 
removal of calcium from the cytoplasm which leads to vasodilation (as 
illustrated in Figure 1.4). The physicochemical properties of this drug, namely 
short biological half-life of 3-5min and instability at pH below 10.5, limits it to 
the intravenous route [51, 52].  
symptoms dizziness, 
headache, nausea 
Bosentan Binds to ETB 
receptor, blocks 











Sildenafil Metabolizes cGMP   Improved symptoms 



















 Another prostanoid analogue available commercially is treprostenil. 
This too has a short half-life, necessitating it to be also given as an infusion. 
Commercial preparation of treprostinil is in the form of a sterile solution which 
can be administered either by the intravenous or subcutaneous route. 
Treprostinil is rapidly and completely absorbed after subcutaneous infusion 
with 100% bioavailability [53].  
 The prostanoid, iloprost, is given as a trometamol salt for intravenous 
administration. Iloprost is administered for idiopathic PAH (IPAH) or when 
























Figure 1.4 Mechanism of action of Prostanoids. IP1 receptor- prostacyclin 



























 Apart from prostanoids, another class of drugs prepared as a parenteral 
solution is the PDE5, for example sildenafil citrate, which is effective in group 
I patients. Both long term [56, 57] and short-term [58] studies on PDE5 
showed that it is effective for patients as there was an improvement in 6-minute 
walk test, increase in vasodilation, reduction in symptoms and a decrease in the 
rate of worsening of symptoms. PDE5 metabolizes cyclic guanosine 3',5'-
monophosphate (cGMP), decreasing its concentration, which in turn lowers 
systemic and pulmonary artery pressure [59, 60]. Inhibitors of PDE5 increase 
the cGMP concentration, stimulating activation of protein kinase G, causing 
vasodilation of the pulmonary artery. Sildenafil is administered as an 
intravenous bolus dose three times a day. 
1.5.2.2 Oral formulations 
 Oral administration is favoured over intravenous as it is improves 
patient compliance, can be self-administered and is non-invasive, eliminating 
the shortcoming of intravenous infusions. Sepsis, a major shortcoming with 
chronic infusions, is also avoided. Research has been on-going to develop oral 
dosage forms of PAH treatments. Bosentan, a non-selective antagonist of the 
ET-1, was the first PAH drug to be given in an oral form. It acts on both the 
ETA and ETB endothelin receptors. ET-1 is a G-protein coupled receptor with 
ETA receptors present on vascular smooth muscle cells and ETB on both 
endothelin and vascular smooth muscles. Both receptors mediate smooth 
muscle cell proliferation [61]. While ETA receptors cause vasoconstriction [62-
64], ETB receptors cause vasodilation and antiproliferative modulator (nitric 
oxide and PGI2) release on endothelial cells. ETB causes vasoconstriction and 
mitogenesis in vascular smooth muscles. Thus, antagonists to this receptor bind 
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to ET-1 to inhibit release of calcium into the cell cytoplasm causing 
vasodilation. Prospective, randomized, placebo controlled multi-centred studies 
have proven that bosentan is effective in IPAH and connective tissue disease-
related PAH [65, 66]. Bosentan is administered as oral tablets twice a day with 
or without food [67]. However oral bosentan is prescribed and dispensed 
initially only through the Tracleer (the trade name for bosentan) Assistance 
Program (T.A.P), not through pharmacies due to its potential to cause liver 
damage and risk to foetus, hence this medication poses major patient 
compliance challenges [65-67]. 
 ET-1 antagonists which bind specifically to ETA receptor were then 
developed to limit the action to the receptor for PAH only. Sitaxsentan has a 
longer half-life compared to bosentan thus requiring once-daily oral dosing. 
Clinical trials of sitaxsentan showed improvement in the 6-minute walk 
distance test, hemodynamics and functional class in patients of PAH [68]. Oral 
abrisentan, another ETA specific antagonist, approved for use in PAH has been 
reported to have optimistic results with minimum adverse effects during 
placebo-controlled trials [69]. 
 Other classes of drugs investigated for oral formulations such as 
sildenafil, a PDE5 inhibitor, are also made available as oral tablets to overcome 
the inconvenience observed with IV bolus administration. 
1.5.2.3 Inhaled formulations 
 With progress in formulation science and new routes explored for drug 
delivery, researchers became interested in the inhalation route for the treatment 
of PAH.  
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 First drug to be administered by this route for PAH was inhaled nitric 
oxide, which when administered with ventilator support and appropriate 
agents, is active in treating persistent PAH of the newborn (PPHN). Nitric 
oxide is an endogenous compound that relaxes vascular smooth muscle by 
binding intracellularly to heme moieties of soluble guanylate cyclase. This 
activates guanylate synthase, resulting in increased synthesis of cGMP and 
subsequent smooth muscle vasodilation. In PPHN, it improves oxygenation 
and reduces the right-to-left shunting of blood flow through the patent ductus 
arteriosus and foramen ovale. It is supplied as a gas for inhalation at 
concentrations of 100 and 800 ppm. It nonetheless suffers from adverse effects 
like hypotension, cellulitis and hyperglycemia. 
 As previously mentioned, treprostenil is a promising drug for PAH, but 
not preferred because of its IV route of delivery. Thus to capitalize on the 
advantageous pharmacological and stability properties of treprostenil, it was 
developed as a solution for inhalation. This is administered by the Tyvaso® 
inhalation system alone with proper precaution. Patients undergoing treatment 
for PAH with oral ET-1 antagonists, bosentan or PDE5 inhibitor, sildenafil, 
were concurrently exposed to inhaled treprostenil and improved patient 
hemodynamics, functional class and exercise capacity were reported [70-73]. 
Iloprost, which was thought to be more beneficial than treprostenil, in terms of 
half-life, was also formulated for inhalation. Iloprost inhalation solution is 
administered using the I-neb(TM) ADD(R) system or the Prodose(R) ADD(R) 
system. This ensures targeted delivery of the drug to the pulmonary vasculature 
reducing the systemic side effects observed in conventional formulations [74].  
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 Apart from administering these drugs alone, several combination 
therapies have also been used to treat PAH. 
1.5.2.4 Combination treatments 
 The hemodynamic effect observed with the PAH drugs is very modest. 
Thus, to improve the effect, some combinations have been tested in clinical 
trials with significant improvement over individual therapies.  
 The combination of inhaled iloprost with bosentan was subjected to a 
randomized placebo-controlled trial, resulting in borderline significant 
improvement in the 6-min walk distance test compared to the placebo [75]. The 
hemodynamics of this combination however did not differ significantly from 
that of individual therapies. 
 Another randomized trial which showed improvement of PAH used 
combination therapy of  sildenafil and epoprostenol The exercise capacity and 
time to clinical worsening were better when compared with epoprostenol alone 
[76]. 
 Adjunct therapy of oral sildenafil in patients suffering from severe PAH 
with ongoing chronic therapy of inhaled iloprost (unchanged dose) also showed 
improved exercise capacity and pulmonary hemodynamics [77]. 
1.5.3 Concerns with available treatments 
 In the earlier sections, the treatment options available in the market 
have been highlighted. However each has its own disadvantages thereby 
affecting its effectiveness.  
1.5.3.1 Intravenous infusions 
 Prostanoids which form the major treatment option available for PAH 
are given as infusions for therapeutic effectiveness.  
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 Epoprostenol, available as a powder, has to be reconstituted at the time 
of administration with a sterile diluent. This indicates that epoprostenol is not 
stable as a solution so has to be reconstituted into a solution immediately 
before administration. Apart from formulation issues, epoprostenol also has a 
tedious administration arrangement. The epoprostenol infusion requires the use 
of a central venous catheter which is implanted and permanently connected to 
an infusion pump. Any interruption in the continuous administration of 
epoprostenol can lead to right ventricular failure [78, 79].  The drug suffers 
from adverse effects of flushing, headaches, photosensitivity, abdominal pain, 
diarrhoea and jaw pain [80]. Tolerance to the drug also develops during the 
period of treatment.  
 Treprostenil, though more stable than epoprostenol, has a short half-life 
such that it has to be administered as continuous infusion to maintain the 
therapeutic action. Other reported side effects are those that are common to 
prostanoids like headache, jaw pain, and diarrhea. 
 In the case of sildenafil, as previously mentioned, it has to be 
administered as an IV bolus 3 times a day which is cumbersome for 
outpatients. 
 Infusions, suffer from their own shortcomings, adding to the 
pharmacological side effects of the above drugs. Thus administration of the 
above formulations has common drawbacks related to the delivery system like 
sepsis, infection, infusion site pain and bleeding [53, 81]. 
1.5.3.2 Oral formulations 
 ET-1 antagonists are given orally to treat PAH. Bosentan, with a short 
half-life, requires increase dosing frequency. Another ET-1 receptor antagonist 
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that binds specifically to ETA receptor, sitaxsentan, was developed. However 
this drug led to fatal liver toxicity and was withdrawn from the market.  
 Sildenafil, apart from being given as an IV bolus also comes in the form 
of oral tablets. This improves compliance compared to its IV bolus form, 
however, it suffers from pharmacological side effects such as nosebleeds, 
headache, upset stomach, flushing and troubled sleeping. Side effects are 
shown to increase when administered along with certain other pharmacological 
agents, namely other PDE5 inhibitors and vitamin K antagonists. Hence this 
drug is not well accepted by patients with PAH. 
1.6 Prostanoids and calcium channel blockers for pulmonary 
hypertension 
1.6.1 Prostanoid: Iloprost 
Prostanoid iloprost is a stable analogue of epoprostenol and is given as 
a trometamol salt for intravenous administration. Iloprost remains stable under 
normal conditions of temperature and light [82].  It also offers a longer 
biological half-life of 30 min as opposed to 1-3 min in case of other 
prostanoids [82]. In terms of potency, dose of iloprost range from between 1-
10 ng/kg/min and that of prostanoids range between 10-50 ng/kg/min. This 
difference in dosages reduce the therapeutic level of drug thereby decreasing 
its side effects [82]. Comparative studies with intravenous epoprostenol have 
shown similar hemodynamic effect in patients [55, 83]. However, despite the 
formulation advantages of IV iloprost over epoprostenol, clinical studies are 
limited in patient sample size and used for heterogeneous forms of PAH [54, 
83]. No conclusive randomized placebo-controlled trials have been done for 
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IV iloprost. Therefore the efficacy of IV iloprost remains largely unknown and 
hence it is not recommended for PAH treatment [84]. 
To capitalize on the superior physicochemical properties of iloprost, it 
was re-formulated as a solution for inhalation. Aerosolized iloprost offers a 
longer half-life compared to other aerosolizable prostanoids. When inhaled, 
iloprost is deposited in the lung parenchyma causing vasodilation of the intra-
acinar pulmonary arteries which surround the alveolar surfaces [85, 86]. Early 
studies on inhaled iloprost carried out by Olschewski and co-workers [87], 
followed by other studies [86, 88-91] concluded that inhaled iloprost has a 
favourable effect on pulmonary hemodynamics with little or no decrease in BP 
in patients with PAH or secondary PH at rest. In another study carried out by 
Blumberg and his team, it was concluded that when a cumulative high dose of 
iloprost was administered to patients, it showed a slight but significant  
decrease in pulmonary arterial pressure [92]. The findings of this study were 
different from earlier studies in which no change in BP was observed.  
Moreover, since the drug is targeted only to the lungs, the effectiveness of the 
drug increased along with a reduction in the systemic side effects.  
Despite its advantages, iloprost has a drawback, its short duration of 
action. After inhalation, the vasodilative effect of iloprost lasts for 6-9 min 
[93]. Therefore it is imperative to administer the aerosol 6-9 times a day. 
Frequent dosing regimen leads to poor patient compliance.  
1.6.2 Calcium channel blocker: Nifedipine 
 In pulmonary hypertension, vasoconstriction and smooth muscle cell 
hypertrophy contribute to the pathogenesis of the disease. Use of vasodilators- 
calcium channel blockers alleviates these conditions. Among the calcium 
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channel blockers, nifedipine, amlodipine and diltiazem are effective in patients 
such that a one-time administration leads to more than 20% decrease in 
pulmonary arterial pressure without a decline in cardiac output [94]. Patients 
who respond to nifedipine therapy achieve prolonged survival, sustained 
functional improvement and hemodynamic improvement [15, 16, 95]. For 
effective therapy, high daily doses are given to patients, 120-240 mg of 
nifedipine per day. Nifedipine is currently administered as oral tablets which 
causes systemic side effects like hypotension, headache, dizziness and 
peripheral edema, When administered as sustained release preparations, the 
systemic side effects especially systemic hypotension are reduced [96].  
Taking into account the benefits and drawbacks of prostanoids and 
calcium channel blockers, an ideal formulation for pulmonary hypertension 
treatment would be one that is available as an aerosol for targeted delivery to 
the lungs to reduce the systemic side effects. Apart from that, a controlled 
release formulation would also be beneficial to reduce the doses administered 
and improve patient compliance.  
1.7 Controlled release inhalation systems 
 Investigations for potential controlled release inhalation systems, 
namely liposomes [97, 98], biodegradable nano and microparticles [97, 99-
107], formation of co-precipitates [97, 108] and complexation with 
cyclodextrins [97] have been conducted.  Encapsulating the drug within a 
biodegradable polymer by spray drying was reported to produce microspherical 
particles for controlled delivery to the lungs [109-111]. 
 Liposomes are extensively investigated for controlled delivery of drugs 
to lungs. They constitute versatile systems of drug delivery which can be 
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formulated in a range of sizes, incorporating both hydrophilic and lipophilic 
drugs. Moreover, the liposomes are constituted of phospholipids which are 
endogenous to the lungs. Pharmacological agents such as anti-asthmatics, 
cytotoxics, anti-microbials and anti-virals have been incorporated in liposomes 
for controlled delivery.  
 Biodegradable microspheres of natural or synthetic polymers offer a 
range of desirable features for targeted and controlled delivery. Microspheres 
can also be prepared over a range of sizes, encapsulating hydrophilic and 
lipophilic drugs with high efficiency. By altering their synthetic processes, the 
delivery rates of the drugs can be altered. In comparison to liposomes, 
microspheres are physicochemically more stable, both in vitro and in vivo. 
Therefore, the drugs can be released at a slower rate with a longer duration of 
action than in liposomes [97]. Better stability also enables easier formulation of 
microspheres into suitable pulmonary delivery systems. Biodegradable 
microspheres have been shown to be non-toxic and non-immunogenic when 
injected.  
 The structures of some drugs can be modified to sustain their actions by 
conjugating the drugs with macromolecules or giving drugs as their prodrugs.  
Prodrugs which are cleaved to the parent drugs by the enzymes present in the 
lungs can be designed to prolong their action in the lungs. Some ȕβ stimulants 
have been modified by esterification to increase their uptake in the lungs and 
slow down their metabolic transformation into the parent drug. This process 
also decreases the cardiovascular side effects of these drugs. Drugs for 
sustained action on lungs have also been conjugated with macromolecules like 
dextran and PEG (polyethylene glycol) by esterification, which are then 
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metabolized by esterase in the lungs, prolonging the drug action producing 
sustained release. Cromoglycic acid conjugate with dextran (CGA-dextran) has 
been shown to have an altered release pattern with that of CGA alone. 
 Altering the dissolution rate of drugs by forming sparingly soluble 
forms of the drug or co-precipitates can also prolong their duration of action in 
the lungs. It has been shown that fluorescein forms a stable co-precipitate with 
magnesium stearate which shows a slower dissolution rate when compared to 
fluorescein solution alone. In order to deposit the drug effectively in the lower 
regions of the respiratory tract using aerosol, the particle size should be 1-5 µm 
increasing the effective surface area exposed to the dissolution medium and the 
rate of dissolution is increased. Hence careful control has to be made between 
the size required and the dissolution rate. Another aspect to consider is the 
safety of the metal hydroxides used to form co-precipitates.  
 Another approach to controlled release aerosols is to form complex 
with cyclodextrins, which are oligosaccharides with 6, 7 or 8 glucopyranose 
units (α, ȕ and Ȗ cuclodextrin respectively). Drugs bind with cyclodextrin via 
non-covalent bonds and are trapped in the apolar core of the cavity, thereby 
conferring controlled release [112, 113]. Of the three cyclodextrins, ȕ form is 
the most effective in altering the release of drugs with which they bind [114, 
115]. The use of cyclodextrins for controlled pulmonary delivery is not 
conclusive as the in vivo stability of these formulations has not been reported. 
1.8 In vitro testing of inhalation controlled release formulations 
 There is a growing interest in pulmonary drug delivery, due to its many 
advantages in treating both local and systemic conditions. The main hurdle in 
developing inhalation formulations is the lack of suitable in vitro release 
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determination methods. Many pharmacopeial methods determine the drug 
release profile of pharmaceutical formulations, with USP type I (basket type) 
and II (paddle type) being the most commonly used. These apparatus are 
designed to mimic GI tract conditions where sink conditions and large volume 
of dissolution medium are used. Researchers used the USP type II apparatus to 
determine the drug release from pulmonary formulations as a proof of concept 
where the idea was to explain the effect of excipients and formulation 
development on the drug release instead of mimicking the lung conditions 
[116, 117]. The USP type II apparatus was recently improvised to make it more 
suitable for testing of pulmonary formulations by incorporating a membrane 
holder in the paddle and sandwiching the sample within the holder [118].  
 Another device used is the USP type IV (flow through apparatus) where 
the formulation is housed between two filters and the liquid flows through the 
housing and the output concentration is measured at different time points [119]. 
This flow through apparatus has been officially approved by the British 
Pharmacopeia for assessment of drug release from novel dosage forms and 
recently was shown to be successful in evaluating dissolution profiles of poorly 
soluble and extended release powder formulations [120] and regarded as the 
method of choice for unconventional dosage forms like microspheres, 
liposomes and stents [121]. Flow through apparatus allows flexibility that 
permits changes to be readily made even within a test run, of important factors, 
such as temperature, flow rate, viscosity, surfactant concentration and pH, all 
the drug particles collected on the filter experience essentially the same 
intensity of solvent flow, thus agitation conditions are related to the solvent 
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flow rate in a meaningful way, and the flow rate of the dissolution media is 
easy to define and to control [122]. 
 The respiratory tract has a large surface area containing mucus and 
other phospholipids, present in a small volume. Thus, evaluating the drug 
release from controlled release formulations in a large volume of medium may 
not be representative of the in vivo release rate in the lungs. An alternative 
approach to simulate lung volume conditions would be a diffusion process 
where the formulation is merely wetted and will diffuse into the surrounding 
media. For this purpose, researchers have used a modified Franz diffusion cell, 
both horizontal and vertical types, where the powder formulation was placed 
on a membrane, previously wetted with the dissolution medium and drug 
release across the membrane at different time points was evaluated [99, 110]. 
This is the most commonly used apparatus for testing pulmonary formulations 
since, however the diffusion across the membrane is limited by drug solubility 
when in contact with the membrane. 
1.9 Objectives and Hypothesis 
Controlled release inhalable formulations allow prolonged drug release 
and targeted delivery to the lungs. Two prominent classes of drugs used for 
pulmonary hypertension treatment are calcium channel blockers (nifedipine) 
and prostanoids (iloprost). Current iloprost formulation (inhalation solution) 
has a short duration of action requiring frequent dosing of 6-9 times/day, 
making it inconvenient for patients. Nifedipine on the other hand is currently 
available as an oral dosage form which leads to systemic side-effects.  
 This thesis work is dedicated to develop controlled release inhalable 
polymeric microspheres that control the drug release to provide a convenient 
28 
 
therapy for patients with reduced dosing frequency and systemic side effects. 
Microspheres were formulated using different excipients to control the drug 
release and have acceptable aerosolization properties. The formulated 
microspheres would be physicochemically characterized using different 
techniques. 
 Currently there is no pharmacopoeial method to determine drug release 
from inhalable formulations. This thesis also attempts to assess the suitability 
of dissolution apparatus used for testing oral and dermal dosage forms to study 
drug release from inhalable formulations with water insoluble drugs. Three 
equipment (USP Type II, Franz vertical diffusion cell, USP Type IV) were 
studied to determine one most suitable for formulated microspheres. An ideal 
equipment to test drug release from inhalable formulations with water insoluble 
drugs should mimic the lung condition in terms of fluid volume with a 
membrane. 
 It was hypothesized that polymeric microspheres which control the 
release of drug to allow less frequent administration and improve the 
compliance to PAH treatment can be formulated. This formulation would 
reside in the lungs for longer duration because of the release modifiers used, 
releasing the drug slowly and consistently over a prolonged period thereby 
reducing the dosing frequency. To assess the drug release from these 
formulations, it was hypothesised that in vitro dissolution equipment which 
mimics the lung environment and is appropriate for testing microsphere 






MATERIALS AND METHODS 
 
2.1 Materials 
 Nifedipine was purchased from Qingdao Dacon Trading Co., Ltd, 
China. Polyvinyl alcohol (PVA) was obtained from Tokyo Chemical Industry 
Co. Ltd. (Tokyo, Japan).  Medium molecular weight (MMW) chitosan was 
purchased from Sigma Aldrich Inc., USA (Brookfield viscosity 200.000 cps). 
Sodium dodecyl sulfate (SDS) was ordered from Fluka Analytical (Seelze, 
Germany). (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 
was supplied by Alfa Aesar (Lancaster, UK). Nutrient Mixture (Ham) F-12 
(1×) was received from Invitrogen (New York, USA). Fetal bovine serum 
(triple 0.1µm sterile filtered) was procured from Thermo Scientific HyClone®. 
Phosphate buffer saline was purchased from Vivantis technologies, Malaysia. 
Flurosphere polystyrene microspheres (1 µm) were purchased from Life 
technologies (California, USA). Ethanol, ethyl acetate and dichloromethane of 
analytic reagent grade were purchased from Fisher Scientific UK Ltd. Acetic 
acid (glacial) 100% anhydrous was obtained from Merck, Germany. Water 







2.2 Development of controlled release inhalable polymeric microspheres 
for treatment of pulmonary hypertension 
2.2.1 Formulation of microspheres by spray drying 
 Microspheres were prepared by the spray drying technique using the 
Büchi Mini Spray Dryer B-290 with a high performance cyclone (Büchi 
Labortechnik AG, Switzerland) and a two-fluid spray nozzle. The 
microspheres were formulated using the method explained in a previous study 
[109].  Briefly, the concentration of PVA was kept constant at 1.5% w/v to 
ensure uniform viscosity of the solutions. The drug concentrations were varied 
to formulate microspheres containing different polymer: drug ratios. Three 
samples of microspheres were prepared with PVA:drug ratio of 50% [MS-1 
(P50:N50)], 70% [MS-2 (P70:N30)] and 90% [MS-3 (P90:N10)] (by weight). 
In brief, nifedipine was dissolved in ethanol and PVA was dissolved in water. 
To solubilise PVA in water, the solution was heated at 90°C for 5 min. A 
homogeneous system was prepared by mixing the PVA-water solution with 
nifedipine-ethanol solution and allowed to stir overnight to aid effective 
mixing. The spray drying parameters were varied to obtain particles suitable 
for inhalation. The inlet temperature was set at 130°C, the outlet temperature 
was found to be between 70 and 75°C. The solution feed rate and the air flow 
rate were set at 3 ml/min and 670 l/h respectively. For maximum efficiency, 
the aspirator of the spray dryer was kept at 100%. Spray dried drug contains 
1.5 g nifedipine in 100 ml ethanol; spray dried under the same conditions as 
used for the microspheres. The spray dried samples were stored at 45% RH and 




2.2.2 Physicochemical characterization of microspheres 
2.2.2.1 Particle size analysis 
 The particle size of microspheres was determined using the laser 
diffraction method. Malvern Particle Size Analyzer MS2000 with Scirocco 
2000 accessory (Malvern, Worcestershire, UK) was used for the determination 
with feed pressure set between 2 to 3.5 bars and feed vibration rate of 50%. All 
samples were tested in triplicate over 2 s intervals. The Scirocco accessory of 
the Malvern Mastersizer allows particle size measurement of dry powders, with 
particle flow controlled by a variable feed-rate vibrating tray. The dispersive 
air pressure can be controlled over a range of 0-4 bar [123]. The rationale for 
using the dry dispersion method for particle size measurement is that for 
inhalation, the dry powders formulated, can be measured more accurately by 
the dry method. 
2.2.2.2 Particle morphology 
 The samples were observed using a field emission scanning electron 
microscope (FESEM, JEOL JSM-6700, Japan) at an acceleration voltage of 5 
kV to compare with the particle size obtained by laser diffraction and also to 
observe the morphology of the particles. Prior to observation, the sample was 
prepared by undergoing static charge elimination (SJ-M300 High-performance 
Micro Static Eliminator, Japan), and dispersed onto adhesive tape-coated metal 
stubs and sputter coated with gold (Cressington 208HR, UK) at 10 mA for  





2.2.2.3 Drug crystallinity 
 X-ray diffraction patterns of raw nifedipine, spray dried nifedipine and 
the drug loaded microspheres were obtained using an X-ray powder 
diffractometer (D8 Advance, Bruker AXS GmbH, Karlsruhe, Germany), 
equipped with PSD Vantec-1 detector. Measurements were performed with 
monochromatized Cu Kα radiation (Ȝ = 1.54β Å) generated at 20 kV and  
40 mA, over the angular range for nifedipine from 4 < βθ < 55° in step scan 
mode (step width 0.017°, scan rate 1°min−1). Both the divergence slit and 
antiscattering slit were 0.3°. 
2.2.2.4 Thermal analysis 
 Microspheres were subjected to differential scanning calorimetry 
(DSC) using SDT 2960 Simultaneous DSC-TGA (TA Instruments, USA) to 
measure their thermal properties. In an open aluminium pan under a 10 ml/min 
stream of nitrogen purge, samples of 2–5 mg were heated from room 
temperature to 200°C at a heating rate of 10 °C/min. 
2.2.2.5 Drug polymer interaction 
 FT-IR absorbance spectra of nifedipine and drug loaded microspheres 
were obtained using the FT-IR spectrometer (Perkin–Elmer, 2000, MA, USA). 
Samples were prepared as a pellet in a KBr matrix. Sixty four scans were 
collected for each sample with a spectral resolution of 4 cm−1. 
2.2.3 Drug distribution within microspheres 
 The Raman spectrum of the microsphere samples was analysed using 
Raman microscope (InVia Reflex, Renishaw).  A 785 nm near infrared diode 
laser was used to excite Raman scattering and the backscattered light was 
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collected by a 50× objective lens. Point-by-point mapping of the samples was 
performed in both x and y directions with a step size of 1.5 µm in an area of 30 
µm × 30 µm. A static 1800 groove per mm dispersive grating was then used to 
collect measurement scans in a spectral window from 400 to 1800 cm-1.  The 
raw spectra collected were a combination of scattering signals, spikes 
generated due to cosmic rays, and background autoflourescence. Spectral 
preprocessing was done by removing spikes followed by baseline correction to 
generate Raman spectrum alone. Band-target entropy minimization (BTEM) 
was then used to reconstruct the pure component data (PVA and nifedipine) 
from the microsphere sample spectra [124]. Of the self-modeling curve 
resolution (SMCR) techniques available, the BTEM algorithm was developed 
to obtain spectra of the pure component of the constituents from a mixture of 
spectra along with reconstructing the spectra of minor components [125, 126]. 
2.2.4 Drug encapsulation efficiency  
 Weighed quantities (25 mg) of microspheres were dissolved in ethanol-
water cosolvent (3:2). The solution was stirred at 400 rpm for 48 h. Samples 
were withdrawn and the drug content was measured with a  UV 
spectrophotometer (Ȝ = βγ7 nm) using a calibration curve [127]. PVA showed 
no absorbance at this wavelength. The drug loading and encapsulation 
efficiency were calculated from the UV data as follows 





2.2.5 In vitro drug release profile 
 Dissolution was performed using 900 ml of 0.5% w/v SDS solution at 
γ7˚C in the USP dissolution apparatus II (VK 7010 dissolution tester, Varian, 
UK). The paddle speed was set at 100 rpm, and 5 ml medium samples were 
withdrawn manually for analysis at specified time-points during the 8 h 
dissolution test. Analysis was done using UV spectrophotometer (Cary 50 
spectrophotometer, Varian, UK) at 237 nm. The dissolution experiment was 
done in triplicate. To ensure that only the drug released from the microspheres 
into the dissolution medium was analysed, the sample was first filtered using 
0.45 µm PTFE syringe filters before UV analysis.  
2.2.6 In vitro microsphere aerosolization 
 The in vitro performance of the spray dried powders was determined 
using the Multi-Stage Liquid Impinger (MSLI, Copley Scientific, Nottingham 
UK), set at a flow rate of 60 l/min from a pump (HCP5 High Capacity Pump, 
Copley Scientific, UK) that was previously calibrated (TSI 4000 Series flow 
meter, Minnesota US). The effective cut-off diameters of stages 1, 2, 3 and 4 at 
60 l/min flow rate were 13, 6.8, 3.1 and 1.7 µm respectively. Before the start of 
experiment, 20 ml of 30% v/v ethanol aqueous solution was introduced to 
stages 1 to 4 of the MSLI, and a filter paper at stage 5. Spray dried powder was 
accurately weighed into size 3 HPMC capsules and loaded into an Aerolizer® 
dry powder inhaler (DPI; Novartis, Switzerland) that was connected to the 
MSLI via a stainless steel USP throat. After the capsule was pierced, the 
powder was released into the MSLI for 4 s at 60 l/min flow rate. The following 
values were obtained from calculations: the fine particle fraction (FPFemitted), 
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which is the percentage of microspheres with aerodynamic diameter less than 5 
µm and the mass median aerodynamic diameter (MMAD). MMAD is defined 
as the median of the distribution of airborne particle mass with respect to the 
aerodynamic diameter and it divides the mass distribution of an aerosol in half 
[109]. Percentage of total FPF is measured taking into account the amount of 
drug that was deposited in the capsule and device which did not enter the 
respiratory tract. Percentage of emitted FPF is calculated excluding the amount 
of drug that was deposited in the capsule and device, indicating the amount of 
drug emitted into the respiratory tract. 
2.2.7 Statistical Analysis 
All data values were reported as mean ± standard error of the mean 
(SEM). Statistical differences were determined using the one-way analysis of 
variance (ANOVA) with Tukey’s test used for post-hoc comparisons. P values 
of < 0.05 were considered to be statistically significant. 
2.3 Enhancement of the formulated microspheres using different 
excipients to improve upon controlled release and aerosolization 
2.3.1 Formulation of microspheres by spray drying 
Microspheres were formulated by the spray drying process as discussed below  
2.3.1.1 Chitosan-EtOH microspheres (Ch-N-EH) 
 Briefly, chitosan gel was prepared by dissolving 2.5 g chitosan in 500 
ml glacial acetic acid aqueous solution (1% v/v) and stirred overnight. The 
resulting gel solution was then subjected to vacuum filtration to remove the 
remaining chitosan that cannot be dissolved by acetic acid solution. Nifedipine 
(69.4 mg) was separately dissolved in 75 ml ethanol. Nifedipine solution was 
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added to chitosan gel (125 ml). Water was added to this mixture to increase the 
final volume of the spray drying solution to 250 ml. The spray drying solution 
thus formed contained chitosan-nifedipine in 90:10 ratio with 30% v/v ethanol 
as solvent. The solution was homogenised (T10 basic Ultra-Turrax high shear 
homogenizer; IKA, Germany) at 9500 rpm for 10 min. The prepared solution 
was then spray dried using a Büchi Mini Spray Dryer B-290 with a high 
performance cyclone (Büchi Labortechnik AG, Switzerland) and two-fluid 
spray nozzle. The spray dryer operating conditions were chosen as, inlet 
temperature of 150˚C, feed rate of 7.5 ml/min, air flow rate of 600 l/h and 
aspirator rate of 100%. The resulting outlet temperature was 62-7β˚C. Spray 
dried drug contains 1.5 g nifedipine in 100 ml ethanol; spray dried under the 
same conditions as used for the microspheres.  
2.3.1.2 PVA-EA microspheres (P-N-EA) 
 Briefly, PVA concentration was maintained at 1.5% w/v in the aqueous 
phase, to minimize viscosity differences between the different liquid feeds. The 
drug concentration was adjusted to keep the ratio of PVA to nifedipine at 
90:10. To prepare the PVA 1.5% w/v solution, the water was heated to 90°C 
for 5 min before gradually adding PVA into the water. The aqueous and 
organic phases containing PVA and nifedipine respectively were then mixed by 
magnetic stirring to form the liquid feed. The feed prepared was a cloudy 
emulsion which was further homogenized (T10 basic Ultra-Turrax high shear 
homogenizer; IKA, Germany) at 9500 rpm for 5 min before spray drying. The 
liquid feed was then spray dried using the Buchi Mini Spray Dryer B-290 with 
a high performance cyclone and a two-fluid spray nozzle. Spray-drying 
parameters, namely the inlet temperature, liquid feed rate, spray gas flow rate 
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and ratio were previously optimized to produce fine microspheres that have a 
narrow particle size distribution [34]. The parameters were set at 130°C, 3 
ml/min, 670 l/h, and 100% respectively.  
 For elemental analysis, confocal and macrophage uptake study, 
felodipine was used as a model drug. The chlorine in felodipine can be easily 
detected by Energy dispersive X-ray (EDX) and the inherent fluorescence of 
felodipine makes it suitable for cell uptake and confocal studies. The 
concentrations and spray drying conditions for nifedipine microspheres were 
used to prepare felodipine microspheres. The spray dried samples were stored 
in a dry cabinet at 45% RH for 48 h before characterization.  
2.3.2 Physicochemical characterization of microspheres 
2.3.2.1 Particle size analysis 
 Same procedure as section 2.2.2.1 was applied with parameters suited 
for this set of microspheres. After optimization of the parameters, the vibration 
feed rate was set at 60%, dispersive air pressure at 2 bars and sampling time at 
2 s.  
2.3.2.2 Morphology 
 Procedure mentioned in section 2.2.2.2 was used to determine 
morphology of microspheres. 
2.3.2.3 Surface mapping 
 Samples were loaded on an adhesive tape-coated metal stubs and 
observed using an EDX (JEOL JSM-6700, Japan) for elemental analysis. EDX 




2.3.2.4 Drug crystallinity 
 Procedure mentioned in section 2.2.2.3 was used to determine the 
crystal nature of drugs within microspheres.  
2.3.2.5 Thermal analysis 
 Procedure mentioned in section 2.2.2.4 was used to determine thermal 
behaviour of microspheres.  
2.3.2.6 Drug polymer interaction 
 Procedure mentioned in section 2.2.2.5 was used to study drug polymer 
interaction in microspheres.  
2.3.3 Ethyl acetate determination in P-N-EA microspheres 
 Ethyl acetate content in the P-N-EA microspheres was determined 
using gas chromatography with flame ionization detector (GC-FID). GC 
analysis was performed with an Agilent 6890N network GC system (Agilent 
Technologies, USA) that consisted of a FID (Agilent Technologies, USA). 
Chromatographic separation was carried out using a DB 5 ms capillary column 
(30.0 mm × 0.32 mm × 0.25 mm; Agilent Technologies, USA) with helium as 
the carrier gas. Split injection (3 µl) was conducted with a split ratio of 10:1. 
The inlet temperature and detector temperature were maintained at 220°C and 
280°C, respectively. Different standard solutions were prepared of ethyl acetate 
in dichloromethane. A stock solution of microsphere sample dissolved in 
dichloromethane was obtained by soaking weighed amount of sample in DCM 





2.3.4 Drug distribution within microspheres 
 Felodipine was used as a model drug for confocal studies because of its 
inherent fluorescent nature. The microspheres were suspended in water and 
covered with cover slip to enable easy viewing and then imaged using a Nikon 
A-1R confocal microscope (Nikon, Japan) to observe the fluorescence intensity 
in the DAPI region of fluorescence as the Ȝmax for felodipine is 440 nm.  
2.3.5 In vitro drug release profile 
 Microspheres were tested for drug release using the USP dissolution 
apparatus II (VK 7010 dissolution tester, Varian, UK) following the same 
procedure as highlighted in section 2.2.5.  
2.3.6 Rate order of drug release 
 The drug release kinetics from the microspheres was analysed using 
various established mathematical models in literature: 
i. Zero order release equation 
  y = kt      (3) 
ii. First order release equation 
  ln (100-y) = -kt     (4) 
iii. Hixson- crowell release equation 
  100- (100-y) ^1/3 = kt   (5) 
iv. Higuchi release equation 
  y = kt ^1/2     (6) 
v. Korsmeyer- Peppas release equation 
  y = kt ^n     (7) 
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Where y stands for percent drug released at time t and k
 
represents the release 
rate constants of each rate equation. For the Korsmeyer - Peppas equation, the 
term n, is a diffusion exponent that describes the drug release mechanism.  
2.3.7 Microsphere microstructure 
 Focused ion beam milling of the samples was performed in a focused 
ion-beam/scanning electron microscope dual beam system (FEI Helios 
NanoLab 200). For sample analysis, accelerating voltage and beam current 
were altered to accommodate the fragility of the material. Parameters set were, 
accelerating voltage of 30 kV and beam current of 100 pA. The powder 
samples were mounted onto adhesive tape-coated metal stubs and coated with 
platinum. The samples were examined under a high resolution field emission 
scanning electron microscope at 2 kV. 
2.3.8 In vitro microsphere aerosolization 
 To assess the aerosolization performance of the sample, impinger study 
was carried out using a Multi-Stage Liquid Impinger (MSLI, Copley Scientific, 
Nottingham UK) using the same procedure as highlighted in section 2.2.6.  
2.3.9 Cytotoxicity screening 
 As the microspheres are intended to confer controlled release of the 
drug, it is necessary to test for the local toxicity of its ingredients, PVA and 
chitosan, on the lungs. The toxicities of these polymers were evaluated using 
cell-based tests on human alveolar basal epithelium A549 cell line. 
Cytotoxicity was assessed by the activity of mitochondrial succinate 
dehydrogenase activity using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) assay [128]. The cells were cultured in nutrient 
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mixture (Ham) F-12 (1×) supplemented with 10% v/v fetal bovine serum and 
1% w/v penicillin – streptomycin solution contained in 10-cm petri dishes and 
incubated in an atmosphere of 5% CO2 at 37°C. After the cells attained 
sufficient confluency (~80%), they were seeded in the 96-well microtiter plates 
(Corning, New York, USA) at a density of 3200 cells per well [111] in 200 µl 
of growth medium. The cells were allowed to grow in the incubator for 24 h. 
2.3.9.1 PVA polymer 
 Before preparing the PVA solution for the test, it was sterilised under 
UV light for 4 h and then solutions of concentrations 10, 1, 0.1, 0.01, 0.001, 
0.0001, and 0.00001 mg/ml were prepared using sterile PBS (1×) solution. 
Phosphate buffered saline was used as a positive control for this test. After 24 
h, the medium was exchanged with fresh medium and 20 µl of each PVA 
concentration and PBS were added to their respective wells. The plates were 
incubated at 37°C in humidified 5% CO2 for 24 and 48 h. After 24 h, the 
medium was again exchanged with fresh medium (200 µl) and 20 µl of MTT 
solution (5 mg/ml) was added to each well. The plate was then incubated for 4 
h before the medium was removed and 150 µl of dimethyl sulfoxide was added 
to each well to dissolve the formazan crystals. The plate was shaken with a 
plate shaker for 5 min to ensure complete solubility of the formazan crystals. 
Finally, the colorimetric assay was carried out by measuring the absorbance at 
595 nm using a Tecan 2000 microplate reader (Tecan, Germany). The relative 
cell viability was calculated as  









Where Atest is the absorbance of the polymer solutions and Acontrol is the 
absorbance of the control (PBS).  
2.3.9.2 Chitosan polymer 
 Chitosan was sterilised under UV light for 4 h before preparing the 
stock solution for the assay. Stock solution of concentration 5 mg/ml was made 
by dissolving sterile chitosan in sterile water. Further dilutions were made from 
the stock solution using sterile water to get solutions of concentration 0.5 
mg/ml, 0.05 mg/ml, 0.005 mg/ml and 0.0005 mg/ml. Sterile water was used as 
a positive control for the assay and same procedure as explained for PVA was 
followed. Equation (3) was used to determine the percentage cell viability for 
chitosan polymer.  
2.3.10 Microsphere lung residence time 
 To determine the uptake of microspheres by macrophage cells, cell 
uptake assay as described previously was carried out [11]. Raw 264.7 
macrophage cells (ATCC TIB-71; Manassass, VA) were seeded at about 
50,000 cells/well into a 24-well plate (Greiner Bio-one GmbH, Germany). The 
medium, DMEM, was removed after 24 h of incubation, and DMEM 
containing control particles (1 ȝm polystyrene particles) were added to 
predetermined wells. Microsphere samples suspended in DMEM were also 
added to the labelled wells. The microparticles (PS and microspheres) were 
added at desired concentrations so that almost equal numbers of each particle 
type were incubated with the cells (about 105 particles/well). A number of 
wells were left without addition of any particles as cell controls. After each 
time point (2 and 24 h), the medium was removed and the cells were washed 
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with PBS. The wells were then imaged with the aid of the Nikon Eclipse TS-1 
fluorescent microscope (Nikon, Japan). 
2.3.11 Accelerated stability study 
 To determine the stability of these microspheres, freshly prepared 
samples were stored under stress conditions of 40°C and 75% RH for a period 
of 3 months. Microspheres were observed for changes in crystal nature, 
morphology and aerosolization profile every month.  
2.3.12 Statistical analysis 
All data values were reported as mean ± standard error of the mean (SEM). 
Statistical differences were determined using the one-way analysis of variance 
(ANOVA) with tukey’s test used for post-hoc comparisons. P values of < 0.05 
were considered to be statistically significant. 
2.4 Comparison of different dissolution apparatus for inhalation 
formulations of water insoluble drug  
2.4.1 USP Type II apparatus  
 The three samples of microspheres prepared previously were subjected 
to in vitro drug release test using the paddle type dissolution apparatus (VK 
7010 dissolution tester, Varian, UK). For each test, 50 mg of each sample of 
microspheres was added to each dissolution bath containing 900 ml of 0.5% 
sodium dodecyl sulphate as the dissolution medium. The test temperature was 
set at 37°C, average body temperature, at a rotation speed of 100 rpm. The test 
was carried out for 6 h and samples were manually withdrawn at each time 
point and drug concentration was measured using the UV spectrophotometer 
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(Cary 50 spectrophotometer, Varian, UK) at 237 nm. Triplicates of each 
sample were tested. 
2.4.2 Franz diffusion cell  
 Drug release of microsphere samples using the vertical Franz diffusion 
cell was also conducted. Glass fibre membranes (Macherey- Nagel Gmbh & 
Co. KG) were used as diffusion barrier for this apparatus.  The membranes 
were soaked overnight in the dissolution medium (0.5% sodium dodecyl 
sulphate) before use. A sample of 10 mg was loaded on the membrane and 
clamped to the diffusion cell. The receptor cell contained 7 ml of the 
dissolution medium. The test was carried out for 6 h and samples were 
withdrawn and different time points. At each time point, all 7 ml of the 
receptor solution was withdrawn and replaced with fresh medium maintaining 
sink conditions. Sample analysis was carried out using UV spectrophotometer 
(Cary 50 spectrophotometer, Varian, UK) at 237 nm. Triplicates of each 
sample were tested. 
2.4.3 USP Type IV apparatus  
 The three samples of microspheres prepared previously were tested for 
drug release using the USP type IV (flow through) dissolution apparatus 
(Erweka Gmbh, Germany) in the open loop setup. In this, 50 mg of each 
sample was sandwiched between two membranes (glass fibre, Macherey- 
Nagel Gmbh & Co. KG) 1.5 cm in diameter. The volume was filled with 1 mm 
glass beads. The test temperature was set at 37°C and the flow rate was set at 8 
ml/min. The dissolution medium was 0.5% w/v sodium dodecyl sulphate, 
which continuously purged the sampling port to maintain sink conditions. The 
45 
 
sample was collected separately and analysed using the UV spectrophotometer 
(Cary 50 spectrophotometer, Varian, UK) at 237 nm over a period of 6 h, 
considering the time needed to setup the apparatus and accounting for the 
photosensitivity of nifedipine. Triplicates of each sample were tested. 
 This chapter outlines the materials and methods used to develop 
controlled release polymeric microspheres which were then characterizped for 
their physicochemical properties and tested for the drug release profiles and 





















DEVELOPMENT OF CONTROLLED RELEASE INHALABLE 
POLYMERIC MICROSPHERES FOR TREATMENT OF 
PULMONARY HYPERTENSION 
3.1 Overview 
Pulmonary hypertension (PAH) is an ailment of the lungs, exhibiting 
elevated arterial pressure and vascular resistance; with a mean arterial pressure 
above 25 mmHg at rest and above 30 mmHg during exercise [35]. Existing 
medications have to be administered frequently, resulting in non-compliance 
by patients.  
Substantial research has been done to develop controlled release 
formulations for pulmonary delivery wherein the drugs are encapsulated in 
polymers, copolymers and lipids. Such formulations include microparticles 
[129, 130] where the drugs were encapsulated within polymers such as 
polyethylene glycol, fatty acids, and copolymer blends to form mesh like 
networks. Liposomes have also been previously developed for sustained drug 
release to treat lung conditions like asthma [131] while formation of co-
precipitates [97, 108] and complexation with cyclodextrins [97] is a promising 
alternative. Encapsulating the drug within a biodegradable polymer by spray 
drying was reported to produce microspherical particles for controlled delivery 
to the lungs [109-111]. Formulation of aerosols requires careful design control 
and comprehension of the particle properties to ensure adequate delivery of 
the drug from the particles to the lungs. Consequently, the particle size has to 
be conserved within a defined range, while maintaining the spherical 
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morphology of the particles. Presently, no commercial formulation is available 
to prolong drug action in the lungs.  
This chapter is aimed at developing a formulation of the drug, 
nifedipine, within microspheres, made from PVA at varied concentrations, 
using the spray drying method, so as to control the rate of drug release. 
3.2 Results 
3.2.1 Physicochemical characterization of microspheres 
3.2.1.1 Particle size analysis 
Particle size distribution of the prepared microspheres is shown in 
Figure 3.1. The size of microspheres was 7.8 ± 0.32 µm for MS-1 (P50:N50), 
13.1 ± 0.65 µm for MS-2 (P70:N30) and 13.9 ± 0.62 µm for MS-3 (P90:N10). 
The particle size of nifedipine (as obtained) was 78.5 ± 3.5 µm. 
  























SEM images of the microspheres (Figure 3.2) showed that they were 
spherical with rough surfaces. It was observed that as the polymer:drug 
concentration increased, the surface of the microspheres became smoother 
(Figure 3.2D and 3.2E). However small amounts of crystals were found on 
their surface, which could be the unencapsulated drug. Not all drug was 
encapsulated within the polymer indicating there was loss of some polymer 
during the spray drying process.   
 
Figure 3.2 Scanning electron microscopy images (A) Nif (B) SD Nif (C) MS-




3.2.1.3 Drug crystallinity 
X-Ray diffraction (XRD) determines the crystallinity of the powder; 
where the volume concentration of, for example, amorphous filler to 
crystalline active matrix, is measured within a dosage form. It is an important 
parameter as it can influence the processing behaviour of a drug as well as its 
pharmacological performance [132]. Figure 3.3 shows the X-ray 
diffractograms of the raw drug, the spray dried drug and the microspheres. 
Presence of sharp peaks in the diffractograms indicates the crystalline nature 
of the compound. The raw and spray dried drug appeared crystalline in nature 
whereas the drug loaded microspheres were found to be X-ray amorphous as 
sharp peaks were absent. 
 


































3.2.1.4 Thermal analysis 
The thermograms of pure nifedipine and drug-loaded microspheres are 
shown in Figure 3.4. For pure drug, characteristic peaks were observed at 
173°C and 289°C due to polymorphism and melting respectively. The sharp 
peak of nifedipine at 173°C broadens in the microsphere samples. Along with 
peak broadening, a slight shift to a higher temperature was also observed. This 
phenomenon indicates the formation of inter/intra molecular bonds between 
PVA and the drug that could be due to hydrogen bonding as stated previously 
[133]. The other peak which was prominent for the pure drug at 289°C was 
absent in drug-loaded microspheres, which inferred that the drug was 









Figure 3.4 Differential thermal calorimetric graphs for raw nifedipine and 






3.2.1.5 Drug polymer interaction 
To gain further insight to the interaction between the drug and polymer 
at various ratios in the microspheres, fourier transformed infra-red 
spectroscopy (FTIR) was performed. The infrared spectrum (Figure 3.5) 
showed characteristic peaks for PVA; C-H broad alkyl stretching band 
between 2850-3000 cm -1 and a small peak at 3608 cm -1 which is due to O-H 
groups in PVA [135]. Nifedipine showed strong peak at ~ 3300 cm -1 due to 
N-H stretching, while the other peaks at 3095 cm -1 and ~ 2900 cm -1 could be 
due to =C-H stretching and C-H stretching respectively [136]. Broadening of 
peak is observed at ~3300 cm-1, which could be either due to overlapping of 
N-H peak of nifedipine with O-H signal of PVA or due to conversion of 
nifedipine from crystalline to amorphous form in microspheres [137]. This 
indicates that there was no chemical interaction between the drug and 
polymer. Another peak noted for pure PVA, nifedipine and all PVA 





Figure 3.5 FTIR spectra of raw nifedipine and PVA controlled release 
microspheres 
 
3.2.2 Drug distribution within microspheres 
The Raman mapping data of the PVA microsphere samples from the 
BTEM technique (Figure 3.6) showed that the drug MS-1 (P50:N50) was 
concentrated at one location and not well distributed throughout the 
microsphere. This drug distribution and the amorphous nature of the drug 
within the microspheres yielded greater drug release during dissolution. For 
MS-2 (P70:N30), the drug was encapsulated within the polymer matrix and 
released in a controlled manner. The improved controlled release profile could 



































Figure 3.6 Raman mapping results of the PVA microspheres taken at different 
locations of microsphere. Each microsphere was mapped for PVA and 
nifedipine concentration. The axes of the score images are in pixels and can be 
directly correlated to distance by multiplying each pixel with 1.5 µm. 
 
3.2.3 Drug encapsulation efficiency 
To determine the drug loading and encapsulation efficiency, the 
nifedipine content in the microspheres was analysed by UV spectrophotometry 
computed using Equations 1 and 2 (section 2.2.4) and shown in Table 3.1. 
From the table, the amount of drug encapsulated was almost same as the 
















encapsulated within the microspheres, but the encapsulation efficiency of MS-
1 (P50:N50) was higher than 100%. This could possibly be due to the higher 
ratio of ethanol:water used when spray drying this sample. A higher ratio of 
ethanol was needed to dissolve the drug added to the spray drying solution. 
Another reason could also be due to loss of PVA during spray drying, which 
decreased the concentration of PVA with respect to nifedipine content in the 
microspheres. 
S.No Formulation Drug loading (%) Encapsulation efficiency (%) 
1 MS-1 (P50:N50) 59.05± 2.52 118.11± 5.05 
2 MS-2 (P70:N30) 27.92± 1.92 93.08± 6.40 
3 MS-3 (P90:N10) 8.21± 0.85 82.18± 8.52 
 
Table 3.1 Drug loading and entrapment efficiency of the different controlled 
release PVA microspheres  
 
3.2.4 In vitro drug release profile 
The release profiles of the prepared microspheres are shown in Figure 
3.7. For MS-1 (P50:N50), a burst release, more than the raw drug, was 
observed. Microspheres with increased polymer:drug ratio (MS-2 (P70:30), 
MS-3 (P90:N10), showed a burst drug release followed by a slower release 





Figure 3.7 In vitro release profile of PVA controlled release microspheres as 
compared to raw nifedipine 
 
3.2.5 In vitro microsphere aerosolization  
The aerosolization of the spray dried samples was analyzed using the 
MSLI. The mass fraction of each spray dried samples was determined at each 
of the stages - capsule, device, throat, 4 stages of MSLI and filter as shown in 
Figure 3.8. From the aerosolization studies, the Fine Particle Fraction 
(FPFemitted) values were obtained. FPFemitted represents the fraction of the 
powder that deposited in the lowest stages of the lungs (equivalent to the 
stages 3, 4 and the filter stage of MSLI). FPFemitted also represents percentages 
of the sample of particle size between 1-5 µm that could be deposited in the 
lungs. The FPF values were found to be 34.9 ± 2.41%, 20.4 ± 2.47% and 
26.45 ± 0.77% for MS-1 (P50:N50), MS-2 (P70:N30) and MS-3 (P90:N10) 
respectively. The mass median aerodynamic diameter (MMAD) of the 
































respectively for MS-1 (P50:N50), MS-2 (P70:N30) and MS-3 (P90:N10). For 
MS-2 (P70:N30), majority of the microsphere particles were found to deposit 
in the first stage of the MSLI. Under these circumstances, the MMAD could 
not be determined accurately and was estimated to be more than 13 µm. 
Statistical analysis shows that there is significant difference (One - Way 
ANOVA, p<0.05) in the FPF values of MS-1 and MS-2, but an insignificant 
























Figure 3.8 In vitro aerosolization profile of the PVA controlled release 
microspheres obtained from each stage of the MSLI which 




For maximum efficiency of the inhaled formulation, the particles should 
be in a size range of 1-10 µm suitable for deposition in the lung. Most of the 
particles larger than 10 µm would deposit in the throat and those smaller than 
1 µm could be exhaled during normal breathing leading to therapeutic failure. 
Thus, the size range of particles of an inhaled formulation has to be stringently 
controlled. It was observed that as the PVA concentration increased, in 
relation to the drug concentration, the particle size of the microspheres also 
increased. However, microspheres remained within the size limits of inhalable 
particles. From the SEM images (Figure 3.2) it was observed that not all drug 
was encapsulated within the polymer indicating there was loss of some 
polymer during the spray drying process.  As PVA is sticky in nature, it has 
the tendency to stick onto the glass vessel wall during spray drying. This 
deposition in the spray chamber could lead to the loss of PVA in the 
microspheres. Such solid deposits left in the spray chamber were observed 
during our experiments and could explain the high encapsulation efficiency 
observed [138]. Some microspheres were irregular in shape (Figures 3.2B and 
3.2C) [139, 140]. Surface roughness and shape irregularities are desirable as 
the area of contact between particles is reduced, so that the agglomerates 
within the powder can be broken down easily into smaller individual particles 
[141]. 
For a controlled release inhalation formulation, the release of the API 
from the formulation must be evaluated. A major drawback of powders 
intended for inhalation is the lack of suitable methods for in vitro evaluation in 
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the pharmacopoeias and literature. However recently, Asada and his group 
used USP type II apparatus to test the dissolution of co-spray dried 
theophylline-chitosan microparticles intended for inhalation [142]. USP type 
II has been used in this chapter as a proof of concept to determine the effect of 
polymer of drug release. For MS-1 (P50:N50), a burst release, more than the 
raw drug, was observed. The reason could be either due to the chemical 
interaction between the drug and polymer leading to the formation of a new 
chemical entity or the amorphous nature of the microspheres. To test for any 
chemical interaction, DSC and FTIR studies were done on the samples. The 
DSC thermogram and FTIR spectra (Figures 3.4 and 3.5), show that there was 
no chemical interaction between the polymer and the drug and the drug was 
molecularly distributed within the microsphere. Therefore, it can be concluded 
that the high release percentage of the drug in case of MS-1 (P50:N50) was 
due to the amorphous nature of the microspheres. This is in good accordance 
with the previous work done, where amorphous form showed greater apparent 
solubility when compared to crystalline form due to formation of a 
supersaturated solution. [34, 143]. Microspheres with increased polymer:drug 
ratio [MS-2 (P70:N30), MS-3 (P90:N10)], showed a burst drug release 
followed by a slower release over the remaining period of dissolution. This 
microsphere system allows for an initial release of a high loading dose of the 
drug at the site of action, which could later be maintained by the system. The 
dissolution profile in Figure 3.7 shows that for raw nifedipine, the amount of 
drug released between 6 h and 8 h was low (10%) as compared to MS-2 
(P70:N30) and MS-3 (P90:N10) in which a significant (20%) amount of drug 
was released. This indicated that after 6 h, the microspheres released more 
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drug, prolonging its release so that the number of doses could be reduced.  The 
in vitro dissolution results could be further explained by Raman microscopy, 
as the drug when encapsulated well within the polymer matrix in case of MS-2 
(P70:N30) and MS-3 (P90:N10) showed a better controlled release profile 
than MS-1 (P50:N50), where the drug is concentrated at one location in the 
microsphere. More work is needed to further improve the formulation. 
3.4 Summary 
Modified release microspheres were developed with the intent to reduce the 
dosing frequency required for pulmonary hypertension treatment to enhance 
patient compliance. These particles prepared by the spray drying technique 
have the size and morphology suitable for inhalation. Particles were of 
amorphous nature with no interaction between the model drug (nifedipine) and 
PVA as seen from the DSC and FTIR results. For MS-2 (P70:N30) and MS-3 
(P90:N10), nifedipine was found to be molecularly distributed within the 
microspheres. In vitro release profile shows controlled drug release from the 
microspheres with PVA as a release modifier. In vitro aerosolization studies 
confirmed the suitability of the formulation to be given via a dry powder 
inhaler (DPI). Overall, this formulation serves as a promising platform for 








ENHANCEMENT OF THE FORMULATED MICROSPHERES USING 
DIFFERENT EXCIPIENTS TO IMPROVE UPON CONTROLLED 
RELEASE AND AEROSOLIZATION 
4.1 Overview 
Pulmonary arterial hypertension (PAH) is a chronic condition, 
characterized by increased blood pressure in pulmonary vasculature and 
secondary right heart failure. It is associated with poor prognosis, and its 
prevalence is estimated to be 15 cases per one million adults.  Among the 
various treatment options available for PAH, the prostanoid class of drugs has 
proven to be the most effective. They act by dilating systemic and pulmonary 
arterial vascular beds and, with sustained long-term usage, altering pulmonary 
remodelling. Presently prostanoids are administered as IV infusions or 
inhalation solutions. Despite their clinical effectiveness, prostanoids have 
short half-lives requiring frequent administration, and thus do not appeal to 
patients. Therefore a sustained release formulation is desirable to limit the 
number of doses required for therapeutic effectiveness. 
  Inhalation drug delivery began as early as 1950s, when the first inhaled 
drug for asthma was developed. Since then research has been continuing in 
this area to develop inhalation products for lung conditions like chronic 
obstructive pulmonary disorders (COPD), asthma, cystic fibrosis etc. These 
formulations allow for localized and targeted delivery to the lungs with 
minimum systemic exposure.  
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In the work done in chapter 3, PVA was used as a release modifier to 
control the drug release [34]. However, a burst release was observed in this 
case. To overcome this burst release effect and improve aerosolization profile 
over previously formulated PVA microspheres [MS-3 (P90:N10)], other 
excipients were explored.  
Among the factors that can affect initial burst release an important one 
is the nature of the liquid feed [144]. Specifically, the nature of the liquid feed 
being a single phase solution or a biphasic suspension/emulsion can affect 
drug deposition within the microspheres. It is hypothesized that microspheres 
prepared from single phase solutions may have drug particles situated on the 
surface, since the drug is uniformly distributed throughout the solution, while 
microspheres prepared from biphasic emulsions, where the drug and polymer 
are separated into distinct phases, may result in better encapsulation of the 
drug [145]. Thus, a sample of microspheres was formulated where ethanol was 
replaced with ethyl acetate as the solvent. 
For another microsphere sample, PVA was replaced with chitosan 
polymer. Chitosan was chosen as the polymer of choice because of its ability 
to effectively control drug release. Chitosan is a hydrophilic linear 
polysaccharide with a cationic character. The strong attractive electrostatic 
force between the negatively charged glycoprotein of mucin in lungs and 
positively charged amino acid of chitosan, makes chitosan a good 
microparticle carrier with bioadhesive property [146].  
For delivery of drugs to the lungs, the effect of mucociliary movement 
is also to be taken into consideration to ensure that the microspheres 
formulated, reside in the lungs for a longer duration and a continuous drug 
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release. Previously, Aspden and his co-workers have shown that chitosan 
delays the mucociliary transport velocity (MTV) in the lungs. With a decrease 
in the MTV, the clearance of the chitosan microspheres in the lungs slowed 
down, thereby ensuring that the microspheres remained in the lung for an 
extended period [147]. Many studies have used chitosan as the polymer for 
inhaled microsphere formulation due to its high biocompatibility, 
biodegradability and low toxicity [140, 142, 148, 149]. However, to date no 
inhalation formulation containing chitosan has been approved by the FDA. 
Nevertheless the advantages of chitosan have still attracted researchers to 
explore sustained inhalation formulation for various indications like asthma 
medication and respiratory infectious diseases. 
Spray-drying is a preferred method to generate fine powders from 
solutions or suspensions. The generation of micron-sized respirable particles 
has become a common method adopted for sustained release inhalation 
formulation [109]. The one-step process permits greater consistency of particle 
characteristics like size and morphology.   
In this chapter, two microspheres Ch-N-EH (chitosan polymer and 
ethanol solvent) and P-N-EA (PVA polymer and ethyl acetate polymer) were 
formulated and evaluated for their release profile and aerosolization 
efficiency. The performance of these microspheres was compared to the MS-3 
(P90:N10) prepared earlier and referred to as P-N-EH in this chapter.  
Spray drying parameters were optimized to attain the desired particle 
size and morphology for the microspheres to be inhaled. The microspheres 
were subsequently tested to determine their particle size, morphology and 
crystallinity. The drug release from the microspheres was determined and 
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compared to the raw drug before aerosolization efficiencies of the spray dried 
microspheres were tested.   
 
4.2 Results 
4.2.1  Physicochemical characterization of microspheres 
4.2.1.1 Particle size analysis  
Particle size (d50) was obtained using laser diffraction as shown in 
figure 4.1. The particle size was 13.91 µm, 4.58 µm and 7.53 µm for P-N-EH, 




Figure 4.1 Particle size analysis of controlled release microspheres 
4.2.1.2 Morphology 
The images obtained from the scanning electron microscope revealed 
that the P-N-EH and Ch-N-EH microspheres were spherical in shape with a 
few irregularities observed (Figure 4.2A, B). The P-N-EA microspheres 
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(Figure 4.2C) were observed to be doughnut shaped with smooth surface. The 
reason for the doughnut shape of P-N-EA microspheres has been previously 
explained by Wang et.al [150]. In the P-N-EA microspheres the ethyl acetate 
solvent gets trapped within the microsphere core and is released slowly upon 
storage, under dry conditions. These microspheres require some time to 
completely dry and remove the ethyl acetate. This time lag results in the 
deformed shape of the P-N-EA microspheres. Particle morphology generally 
shows smooth surface. However some roughness is observed at a few places 
on the surface which could be due to the drug that was not fully encapsulated 
[141]. Such roughness allows for greater friction among the micron sized 












Figure 4.2 Scanning electron microscopy images (A) P-N-EH (B) P-N-EA 











4.2.1.3 Surface mapping 
To determine the composition of the particles observed on the surface 
of microspheres, EDX was carried out. EDX is an elemental analysis 
technique which can recognize certain elements of the periodic table. For 
elemental analysis, felodipine-loaded microspheres were used and analysed 
for the presence of chlorine (Cl) atom.  
From the EDX image (Figure 4.3) it can be seen that chlorine was 
found to be present on the surface of the microspheres, indicating that the 
particles observed was indeed the unencapsulated drug. However chlorine was 
present in trace amounts, indicating good drug encapsulation. 
 
 
Figure 4.3 Energy dispersive X-ray images of (A) Felodipine (B) P-F-EH (C) 





Formulation Chlorine content on surface (%) 
P-F-EH  0.27 ± 0.08 
P-F-EA  0.30 ± 0.12 
Ch-F-EH  0.39 ± 0.11 
 
Table 4.1 Chlorine content found on the surface of microspheres from EDX 
analysis 
 
4.2.1.4 Drug crystallinity 
XRD analysis results are shown in Figure 4.4 for raw nifedipine, spray 
dried nifedipine, and microspheres. No sharp peaks were observed for 
microsphere samples indicating that the drug became X-ray amorphous during 
the spray drying process. 
 
 
































P-N-EH with 1% raw drug 
P-N-EA with 1% raw drug 
Ch-N-EH with 1% raw drug 
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4.2.1.5 Thermal analysis 
The microsphere samples were analysed using differential scanning 
calorimetry (DSC). The DSC thermograms (Figure 4.5) showed an 
endothermic peak at 175°C in raw nifedipine, which indicates polymorphism 
of nifedipine. Peak at 289°C indicates drug melting. This peak broadens in the 
microspheres confirming the amorphous nature of the drug as was seen in 












Figure 4.5 Differential scanning calorimetric thermograms of nifedipine and 
microspheres 
 
4.2.1.6 Drug polymer interaction 
The microsphere samples along with controls (chitosan, PVA and 
nifedipine) were analysed by FTIR, to ascertain any chemical interaction 
between the drug and polymer that could have formed during spray drying. 
The spectra of the samples are shown in Figure 4.6. The spectra showed 







cm-1. For nifedipine, peaks were observed at ~3300 cm-1 due to N-H 
stretching, 3095 cm-1 and ~2900 cm -1 due to =C-H stretching and C-H 
stretching respectively [136]. Chitosan showed peaks at ~2850 cm-1 and ~3500 
cm-1, due to C-H stretching and O-H bonding respectively [151]. PVA peak 
~2900 cm-1 could be due to C-H stretching. The microspheres showed peak 
broadening at ~3300 cm-1 which could be due to conversion of nifedipine from 
crystalline state, in raw form, to amorphous state, in microspheres, as 
previously shown previously by the XRD studies. The FTIR results suggest 
absence of chemical interactions between polymer and nifedipine. 
 
 























4.2.2 Ethyl acetate determination in P-N-EA microspheres 
The ethyl acetate content in the microspheres was determined to ensure 
aerosol safety of the formulation. First, a calibration curve was plotted using 
different concentration standard solutions. The area under the curve was 
determined for the microsphere samples and compared to that obtained from 
standard solutions. From the GC micrographs (Figure 4.7), it was detected that 
the ethyl acetate was present at 5.17 ppm which accounts to 0.395 % w/w of 
the sample. This has been regarded as safe in terms of residual solvent by the 
US FDA [152] which limits the ethyl acetate content to 5000 ppm per day. 
Previously it has been stated that ethyl acetate evaporates slowly from the 
spray dried samples. The ethyl acetate content in the freshly spray dried 
sample was measured to determine the maximum solvent content present in 
the microsphere at any given time. Since the solvent content of freshly 
prepared sample was less than the allowed limit, the sample would be safe for 
inhalation as upon storage the ethyl acetate will evaporate and its content will 
further decrease. 
 
Figure 4.7 Gas chromatogram of microsphere sample 
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4.2.3 Drug distribution within microspheres 
To understand the distribution of drug within the microspheres, 
felodipine microspheres were viewed under a confocal laser microscope, 
where the drug being fluorescent in nature is illuminated whereas the polymer 
appears dark. The microspheres images (Figure 4.8 B, C, D) show a brightly 
illuminated core with a prominent shell. Absence of the shell in pure drug 
(Figure 4.8 A) indicates that the shell is the polymeric coat, with the drug 





Figure 4.8 Confocal laser microscopy images of (A) Felodipine (B) P-F-EH 








4.2.4 In vitro drug release profile 
The drug release profile of microspheres obtained from USP type II 
apparatus are shown in Figure 4.9. The graphs indicates that the microspheres 
successfully controlled the drug release when compared to raw drug, with, P-
N-EH microspheres showing fast drug release, P-N-EA microspheres showing 
a  burst release followed by controlled release and Ch-N-EH microspheres 
depicting slowest drug release. 
 
Figure 4.9 Drug release profile of microspheres as obtained from USP type II 
dissolution apparatus 
 
4.2.5 Rate order of drug release 
The drug release data from microspheres was analysed using the earlier 
mathematical models by calculating R2 values and used as markers for rate 
order determination. Due to the burst release observed in P-N-EH 
microspheres, the release data fit better when separated into two different time 

































(R2 = 0.41). For P-N-EA microspheres, the drug release was in accordance 
with Korsmeyer- Peppas rate equation (R2 = 0.999). The drug release in  
Ch-N-EH microspheres was as per Higuchi equation (R2 = 0.9893). For 
P-N-EH, the drug release was diffusion controlled with Higuchi release 
observed in the initial phase followed by first order diffusion release. The 
Korsmeyer-Peppas release observed in P-N-EA microspheres suggest that 
drug release was due to drug diffusion through the polymeric matrix and 
erosion of the polymeric microspheres [153]. Higuchi release mechanism 
observed in Ch-N-EH microspheres suggested that the drug released from the 
microspheres by diffusion process. Previous studies have shown that chitosan 
swells in contact with an aqueous medium [154]. The dissolution medium 
used in this study (0.5% SDS) may lead to a similar swelling in the Ch-N-EH 
microspheres. Higuchi release kinetics and chitosan swelling tendency explain 
the sustained release of the drug from the microspheres. 
4.2.6 Microsphere microstructure 
For an aerosol formulation, the factors that affect the aerosol efficiency 
are particle morphology and roughness, particle internal structure 
(hollow/solid) and particle size. To observe the microstructure, an ion beam 
was used to slice the particles which were then observed under an electron 





Figure 4.10 Focused-ion-beam milling images of microsphere samples 
 
From the Figure 4.10 it can be seen that all microspheres have a hollow 
interior with a “golf ball” surface observed in Ch-N-EH microspheres and a 
corrugated surface in P-N-EA microspheres.  
4.2.7 In vitro microsphere aerosolization 
The aerosolization of the microspheres was analysed using the MSLI. 
The mass fraction of the samples was determined at each of the stages - 
capsule, device, throat, 4 stages of MSLI and filter as shown in Figure 4.13. 
From the aerosolization studies, the Fine Particle Fraction (FPFemitted) values 
were obtained. FPFemitted represents the fraction of the powder that deposited in 
the lowest stages of the lungs (equivalent to the stages 3, 4 and the filter stage 
of MSLI). FPFemitted also represents percentages of the sample of particle size 
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between 1-5 µm that could be deposited in the lungs. Table 4.2 lists the FPF 
and MMAD of the three microsphere formulations. 
 
Formulation FPF(%) MMAD(µm) 
P-N-EH 26.45 ± 0.77  12.08 ± 0.60  
P-N-EA 59.12 ± 2.10 4.66 ± 0.15  
Ch-N-EH 51.53 ± 0.01 5.26± 0.13 
 
Table 4.2 FPF and MMAD values of microsphere samples 
 







Figure 4.11 In vitro aerosolization efficiency of microsphere samples, as 
obtained from the MSLI 
 
It is evident from the graph that P-N-EA microspheres have the best 
aerosolization profile among the three formulated microspheres, followed by 
Ch-N-EH and lastly P-N-EH microspheres. Statistical analysis show that there 
is significant difference (One-Way ANOVA, p < 0.05) in the FPF values of 




4.2.8 Cytotoxicity screening 
MTT assay is a proven and commonly used test to determine cell 
viability. In this assay, viable cells are detected by the presence of active 
mitochondrial succinate-tetrazolium reductase that converts MTT to formazan 
crystals by reduction which can then be analysed by colorimetric 
determination. For this assay, human alveolar basal epithelium cell line 
(A549) was used [111, 155]. 
4.2.7.1 PVA polymer 
MTT cell assay was carried out over a period of 48 h and a high cell 
viability percentage was noted (Figure 4.12). Analysis of the test data showed 
that there is an insignificant difference (independent t-test, p > 0.05) between 
the cell viability percentage at 24 and 48 h. The in vitro results showed that 
PVA was non-toxic to lung epithelial cells. 
 




























4.2.7.2 Chitosan polymer 
To ascertain the effect of chitosan on local lung epithelial cells, after 
prolonged contact, the test was carried out for 48 h. The cell viability levels 
over the test period are shown in Figure 4.13. A range of concentrations from 
5 mg/ml to 0.005 mg/ml were tested for the cytotoxicity test. The results 
indicate that after 48 h of exposure to chitosan, the cell number remained at  
90 - 100% of cell viability at starting point, concluding that chitosan is a 
biocompatible polymer for inhalation.  
 
 
Figure 4.13 Cell viability after 24 and 48 h of exposure of A549 cells to 
chitosan 
 
4.2.8 Microsphere lung residence time 
In the lungs, macrophage cells are present that remove particles within 
the size range of 0.5 - 5 µm by phagocytosis. Since the particle size of the 

























macrophages could pose a threat to their residence within the lungs. The 
controlled release microspheres formulated are designed to reside within the 
lungs for a longer duration to release the drug over a prolonged period of time. 
With this aim, macrophage cell uptake was studied for P-N-EA and Ch-N-EH 
and compared to control polystyrene particles 1 µm in size. The results from 














Figure 4.14 Macrophage uptake of microspheres and control particles at 2 h 
and 24 h incubation time-points    
 
In Figure 4.14, left column (A) showcases the control particles and the 
right column (B) showcases the microspheres. After each time point (2h and 



















taken up by the macrophages. At the end of 2 h, the difference between the 
control and microspheres was not discernible. However, at 24 h time - point 
there was a contrasting difference in the control and sample images. In column 
A, many visible fluorescent spots were seen, with very minute amounts of 
fluorescent particles observed in column B. This is because, in column A, the 
control particles were taken up by macrophages and therefore were not 
washed away by PBS as observed under the fluorescent microscope. However, 
in column B, the microspheres are not taken up by the macrophages even after 
24 h and were easily washed away with PBS. This explains the presence of 
very few fluorescent particles in column B. The images suggest that the 
microspheres resided in the lung for a prolonged period to release the drug. 
4.2.9 Accelerated stability study 
The microsphere samples were analysed for their stability under stress-
test storage conditions of 40°C and 75% RH. At each time point, microspheres 
were tested for the effect of stress storage conditions on particle morphology, 
drug crystallinity and aerosolization efficiency.  
4.2.9.1 Morphology 
The effect of stress-test storage conditions on morphology for each 








(a) P-N-EH microspheres 
 
Figure 4.15 Morphology of P-N-EH at (A) Month 0 (B) Month 1 (C) Month 2 
(D) Month 3 
 
From Figure 4.15, it can be seen that with time the microspheres became 
doughnut shaped. This could be due to the slow release of ethanol under high 




(b) P-N-EA microspheres 
 
Figure 4.16 Morphology of P-N-EA at (A) Month 0 (B) Month 1 (C) Month 2 
(D) Month 3 
 
The SEM images show that the microspheres retained their morphology 













(c) Ch-N-EH microspheres 
 
Figure 4.17 Morphology of Ch-N-EH at (A) Month 0 (B) Month 1 (C) Month 
2 (D) Month 3 
 
The SEM images show that the microspheres retained their 
morphology under stress-test storage conditions for 3 months.  
4.2.9.2 Drug crystallinity 
The effect of stress-test storage conditions on drug crystallinity for each 










(a) P-N-EH microspheres 
 
 




(b) P-N-EA microspheres  
 





(c) Ch-N-EH microspheres 
 
 
Figure 4.20 X-ray dffractograms of Ch-N-EH under stress-test storage 
conditions 
 
Lack of sharp peaks show that the drug in the formulations remained 
X-ray amorphous even after 3 month stress-test storage at stress conditions. 
4.2.9.3 Aerosolization efficiency 
The effect of stress conditions on aerosolization efficiency for each 










(a) P-N-EH microspheres 
 
 
Figure 4.21 Effect of storage conditions on FPF of P-N-EH microspheres 
Figure 4.21 shows the effect of stress storage conditions on the aerosol 
efficiency of the microspheres. It can be seen that the change in FPF is gradual 
over the months and statistical analysis shows that the change in FPF from one 
month to the next is insignificant, though a significant difference (One-Way 
ANOVA, p < 0.05) in FPF between the sample at month 0 and month 3 exists. 
However a batch stored under controlled conditions of 25°C and 40% RH 
retains its aerosol properties with an insignificant difference (One-Way 






(b) P-N-EA microspheres 
 
Figure 4.22 Effect of storage conditions on FPF of P-N-EA microspheres 
From the aerosol stability data, it can be seen that under initial stress 
conditions, the FPF significantly reduces after 1 month. This FPF reduction is 
also seen in the second month. This FPF reduction could be due to the initial 
increase in the MMAD of the microspheres. However, after the second month, 
the MMAD stabilised and the decrease in FPF after the second month was not 
significant. However a batch stored under controlled conditions of 25°C and 
40% RH retained its aerosol properties with an insignificant difference 







(c) Ch-N-EH microspheres 
 
Figure 4.23 Effect of storage conditions on FPF of Ch-N-EH microspheres 
Statistical analysis of the stability data over three months showed that 
the microsphere samples maintain their aerosol efficacy over a period of 2 
months under stress conditions. In the third month however, the FPF reduced 
significantly (One-Way ANOVA, p < 0.05). However a batch stored under 
controlled conditions of 25°C and 40% RH retains its aerosol properties with 
an insignificant difference (One-Way ANOVA, p < 0.05) between FPF at 








Table 4.3 Summary of the accelerated stability study for the microspheres 
 
4.3 Discussion 
In this chapter, the previously formulated MS-3 (P90:N10) was 
improved upon by incorporating different excipients. Two different 
microsphere samples were formulated; one where chitosan was used as the 
polymer to control drug release instead of PVA and another one where 
ethanol-water cosolvent was replaced with ethyl acetate-water cosolvent. 
Particle size data shows that P-N-EA microspheres have the smallest size, 
followed by Ch-N-EH and P-N-EH microspheres. In all cases, some particles 
were observed on the surface which were the unencapsulated drug, albeit 
present in trace amounts.  
Confocal microscopy images showed that the drug was concentrated 
within the microsphere core, thereby limiting the drug release from these 
microspheres. Drug release profiles of the microspheres were seen in Figure 
4.9. The graph shows that the drug release was reduced when the formulation 
cosolvent was changed from ethanol-water to ethyl acetate-water. This proved 
the hypothesis that drug release is indeed restricted when the cosolvent has 
two immiscible phases as compared to a cosolvent with miscible phases. The 
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drug release was lowest in chitosan microspheres. This can be explained by 
the solubility of chitosan in the dissolution medium. It is known that the 
solubility of chitosan depends on the pH of the medium. Under acidic 
conditions, chitosan is known to dissolve at a faster rate than at neutral pH 
[156]. The pH of the dissolution medium used (SDS 0.5%) was found to be 
7.9 which is close to the lung fluid pH of 7.4. Thus at the pH of the dissolution 
medium used, chitosan dissolved slowly, limiting the drug release form the 
microspheres and forming a suitable system for controlled release.   
For powder samples, certain physical characteristics affect their 
aerosolization efficiency. These are particle size and morphology, surface 
roughness, particle internal structure (hollow/solid) and. For P-N-EH 
microspheres, the particles were spherical and hollow with smooth surface and 
coarse particle size. These factors result in lower FPF and higher MMAD 
values for this microsphere sample. P-N-EA microspheres were doughnut 
shaped and hollow with corrugated surface and finer particle size that led to 
high FPF value.  For Ch-N-EH microspheres, particles were spherical and 
hollow with “golf ball” surface and fine particle size which resulted in an 
acceptable aerosol profile for Ch-N-EH microspheres. 
4.4 Summary 
Improved dissolution profile was observed for P-N-EA and Ch-N-EH, 
with a more sustained drug release. The FPF was also much higher for these 
microspheres, a significant improvement over the P-N-EH. In vitro 
cytotoxicity assays showed that the polymers, PVA and chitosan, were not 
toxic to the lung epithelial cells upon prolonged exposure. Cell uptake study 
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revealed that microspheres would not be taken up by the macrophages within 
the lungs residing for a longer duration for drug release. The stability study 
depicted a relationship between the FPF of samples and relative humidity, 
with the samples retaining their aerosol properties up to 6 months under 

























COMPARISON OF DIFFERENT DISSOLUTION APPARATUS FOR 
INHALATION FORMULATIONS OF WATER INSOLUBLE DRUG 
 
5.1 Overview 
Pulmonary drug delivery systems offer several advantages when 
inhaled, for both local and systemic conditions. In the recent years there has 
been a growing interest in development of different pulmonary formulations 
for delivering drugs to the respiratory tract. One of the key areas of interest to 
formulation scientists has been the development of controlled release 
formulations which ensure a longer residence time of the API in the lung 
environment and reduce the dosing regimen for the patients. However, till date 
no controlled release formulation is available in the market for patient use 
[97]. A major hurdle in developing such formulations is the lack of standard 
methods to test the drug release.  
In a pulmonary formulation, particle size and aerodynamic diameter 
determine the drug deposition in the lungs and thus are carefully designed. But 
for a controlled release system, the release of API from the formulation matrix 
is also of importance.  
In this chapter, three different dissolution apparatus; USP type II 
(paddle), USP type IV (flow through) and Franz diffusion cell were used to 
test the formulations prepared in chapters 3 and 4. 
Lack of a standard pharmacopeial method for inhalation systems has 
led to a plethora of equipment and methods used to assess their drug release. 
From literature review, an ideal apparatus should have the following features: 
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(a) As the volume of human lung fluid is miniscule (~1 µl cm2) [110] the 
apparatus should mimic lung condition to present the drug release 
profile in a small volume of dissolution medium. 
(b) After inhalation, a formulation dissolves in the lung fluid and diffuses 
across the lung membrane to enter the blood stream. Hence the 
diffusion of the inhalation sample across the membrane must also be 
incorporated into the test. However, the drug release should not be 
significantly impeded by membrane diffusion, thereby limiting the 
range of drugs that can be tested by such an apparatus. 
(c) The apparatus should allow the entire sample amount to experience 
same intensity of flow for a representative drug release profile. In 
equipment where the medium volume is large, the sample may float on 
top thereby giving a false profile. 
(d) Lastly, care should be taken to ensure that sink conditions are 
maintained to avoid saturation of the dissolution medium, especially 
when a small volume of medium is being used. 
5.2 Results 
5.2.1 USP Type II apparatus (Paddle) 
In the paddle apparatus, sample was added to 900 ml of medium. Since 
the lung fluid volume is comparatively less than the medium volume used in 
this apparatus, this equipment only serves as a proof of concept to showcase 
the control of drug release from the microspheres as compared to the raw drug 
instead of mimicking the lung conditions. Figure 5.1 shows the drug release 
from the three microsphere samples previously formulated, as obtained from 





Figure 5.1 In vitro release profiles of microspheres as obtained from USP type 
II apparatus 
 
From Figure 5.1, it is evident that a burst release is seen in case of P-N-
EH with Ch-N-EH controlling the drug release most efficiently. The USP type 
II apparatus has its pros and cons when used for inhalation formulations as 
highlighted in Table 5.1. 
 
5.2.2 Franz diffusion cell 
Franz diffusion cell mimics the lung condition in terms of the volume 
of the cell and diffusion of the sample across a membrane. Figure 5.2 shows 
the drug release profile of the microsphere samples obtained using the vertical 





































Figure 5.2 In vitro release profiles of microsphere samples obtained using the 
vertical Franz diffusion cell 
 
From Figure 5.2 it can be seen that there is overlapping of the drug 
release profiles and difficulty in distinguishing the samples’ release profile, 
moreover the drug release is limited by the membrane and lower than that seen 
in flow through and paddle systems. The pros and cons of this apparatus for 
inhalation systems are highlighted below. 
5.2.3 USP Type IV Apparatus (Flow through) 
The flow through apparatus contains the microsphere sample sandwiched 
between two filter membranes and provides sink condition for the drug release 
from the microsphere samples. Flow through apparatus in the open loop setup 
has been shown to be most appropriate when determining the drug release 
from new dosage forms of water insoluble drugs [5]. Figure 5.3 shows the 






































Figure 5.3 In vitro release profiles of microspheres obtained using the USP 
Type IV dissolution apparatus  
 
There are differences between the release profiles of the three microsphere 
samples with Ch-N-EH being most efficient in controlling the drug release.  
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Table 5.1 (Continued) Comparison of different dissolution apparatus for 
prepared inhalation formulations 
 
5.3 Discussion 
The USP Type IV provides a system where the solvent continuously 
flow through the sample and the drug release is not dependent on diffusion 
across the membrane alone. The flow rate can be modified to alter the receptor 
volume to mimic lung conditions. Sink conditions with the continuous flow of 
fresh dissolution medium and output of filtered solvent containing the 
dissolved drug. This flow through non-recycled system is a suitable set-up to 
study the dissolution kinetics of poorly water-soluble drugs and allows 
changes to be readily made even within a test run, of important factors, such as 
temperature, flow rate, viscosity, surfactant concentration and pH. Drug 
particles collected on the filter would essentially be subjected to same intensity 
of solvent flow, thus agitation conditions would be related to the solvent flow 
rate in a meaningful way, and the flow rate of the dissolution media would be 
easy to define and to control. This technique can be used to examine aerosol 
formulations which are intended to extend the residence time of drugs 
delivered to the lungs which may alter onset and duration of activity by 
sustaining therapeutic drug levels. The results from this chapter reiterate the 
findings from a previous study done by Davies and his co-workers [5]. In this 
study, authors studied the USP type IV apparatus previously used for oral and 
dermal purposes to assess their suitability for inhalation aerosols. They 
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concluded that the flow through apparatus is most appropriate for testing drug 
release from inhalation formulations of poorly water-soluble drugs. In this 
chapter, three available set-ups for dissolution and drug release testing of oral 
and delivery systems were evaluated and compared (Table 5.1) to provide a 
comprehensive overview of their pros and cons to determine the suitable 
equipment for the formulated microspheres. In USP Type II and Type IV 
apparatus, after 6 h of dissolution testing, 70-80 % of drug was released. 
While, in Franz diffusion cell, after 6 h of testing, only 30-40 % drug release 
was observed with only ~10% release in Ch-N-EH microspheres. The results 
suggest that for water insoluble drugs, the drug release was inhibited by the 
membrane in Franz cell as there was no sample - solvent  interaction. In flow 
through cell, the drug release is a function of membrane diffusion and solvent 
dissolution, aiding drug release from the formulated microspheres. Thus to 
conclude, USP type IV (flow through) in an open loop set-up was most 
suitable for the inhalation microspheres formulated previously in the thesis. 
5.4 Summary 
With a recent interest among researchers in the field of pulmonary drug 
delivery, the lack of a standard pharmacopeial method to assess the drug 
release from inhalation systems has resulted in a plethora of methods. While 
many authors have reported the superiority of one equipment over another [5, 
110], this cannot be generalised for all APIs as the diffusion controlled system 
adopted and the solubility of the drug and its excipients would affect the in 
vitro drug release profile. A thorough review of the advantages and 
disadvantages of the different dissolution apparatuses was done to understand 
the factors that affect drug release so as to determine which is most suitable for 
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inhalation formulations. For the inhalation microspheres developed in this 



























CONCLUSIONS AND FUTURE WORK 
 
In this thesis, novel polymeric microspheres were formulated to 
reduce the dosing frequency of pulmonary hypertension medication regimen. 
The formulated microspheres offer a more convenient therapy for patients. 
Apart from formulation, the thesis also addresses the issue of lack of standard 
pharmacopoeial methods for testing drug release from inhalation 
formulations. Three different dissolution apparatus were studied, weighing 
their pros and cons to evaluate suitability for the formulated microspheres. 
6.1 Conclusions 
Three different microsphere formulations were developed, with 
varying polymer-drug ratios to determine the most appropriate for controlling 
drug release. Microspheres formulated were characterized for their 
physicochemical properties like particle size, morphology, crystalline nature 
of encapsulated drug, thermal properties and polymer-drug interaction. 
Raman mapping showed that the drug distribution within the polymer matrix 
was more uniform in microspheres with higher polymer-drug ratio. Among 
the three microspheres formulated [MS-1 (P50:N50), MS-2 (P70:N30), MS-3 
(P90:N10)], MS-3 (P90:N10) showed the slowest drug release. Thus this 
microsphere formulation was selected for further development of controlled 




The microsphere formulations were further improved using different 
excipients, to influence the drug release and aerosolization properties as 
follows: 
i. Ethanol solvent replaced with ethyl acetate solvent (P-N-EA), to obtain a 
biphasic emulsion to ensure better drug encapsulation 
ii. PVA polymer replaced with chitosan polymer (Ch-N-EH), because of its 
bio-adhesive property and ability to decrease mucociliary transport 
velocity, prolonging formulation residence time within lungs 
A significant improvement in the drug release profile was observed for 
Ch-N-EH microspheres. The aerosolization profiles of both the microspheres 
(P-N-EA and Ch-N-EH) improved significantly compared to MS-3 
(P90:N10), with high FPF values and MMAD well within the inhalable 
particle size zone. FIB images showed that the microspheres were hollow 
providing a better understanding of their aerosolization behaviour. 
Macrophage uptake study suggested that considerable amount of 
microspheres could potentially reside within the lungs and not taken up by the 
macrophages after 24 hours, reinstating that the microspheres would release 
the drug over a prolonged period, allowing fewer doses to be administered. 
The stability studies suggested that the FPF of the microspheres was affected 
by the high relative humidity of the storage environment (75% RH). 
However, if stored under controlled conditions of 25°C and 45% RH, for up 
to 6 months, there was no significant difference in the FPF of formulations.  
A thorough search of literature for dissolution apparatus used to evaluate 
inhalation formulations was conducted and few pharmacopoeial methods 
were available for evaluating inhalation formulations. The USP type II 
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apparatus provided a good proof of concept to study controlled release, but 
did not mimic the lung environment due to the large volume of dissolution 
medium used. The Franz vertical diffusion cell provided a small volume, 
mimicking lung conditions but was not suitable for water insoluble drugs as 
drug release is dependent on the diffusion of the drug across the membrane by 
the solvent. USP type IV apparatus (flow through) in the open loop setup 
offered features suitable for inhalation powder testing as the drug release is 
not dependent on diffusion across the membrane alone, flow rate can be 
modified to alter the receptor volume to mimic lung conditions and sink 
conditions can maintained. Of the three apparatus evaluated, USP type IV is 
thought to be a suitable technique to study the dissolution kinetics of poorly 
water-soluble drugs presented as inhalation dosage forms. 
The results conclude that these Ch-N-EH microspheres provided a 
platform for further development of controlled release inhalable formulation 
where a significant decrease in drug release, and thus dosing frequency, was 
observed along with a good aerosol performance. If stored under controlled 
humidity conditions, the microspheres retained their aerosol properties for at 
least 6 months. For the developed formulations, USP Type IV (flow through) 
apparatus in open-loop setup seemed most appropriate.  
6.2 Future directions 
Nifedipine formulations were developed and studied in this thesis. Iloprost is 
also one of the drugs of choice for pulmonary hypertension which has few 
side effects and offers good relief from symptoms. Lack of a good platform to 
understand mechanism of drug release from microspheres and engineering 
particles for inhalable formulations prevented the current study from using 
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iloprost, which is an expensive investigational drug. With a better 
understanding of inhalation microspheres provided by this thesis, 
microspheres with iloprost can be also be developed.  
The in vitro results from this thesis showed a controlled drug release 
profile, paving the way for future in vivo animal studies to ascertain the drug 
release from the microspheres and the deposition of the microsphere samples 
within the lungs upon inhalation. For lung deposition studies, the sheep is a 
good animal model as its lung size is close to that of the human lung.  
Accelerated stability study was carried out for microsphere samples 
(P-N-Eh, P-N-EA, Ch-N-Eh) in this thesis. However, to understand the 
stability of the inhalation powders in real-time storage conditions, suitably 
weighed powders should be put in capsules and stored in active vials to 
simulate blister packaging of capsules as available in market. The filled 
capsules should then be stored at different humidity and temperature 
conditions to determine the real-time storage conditions. To provide patients 
with an acceptable formulation with a longer shelf life, stabilizers like tween, 
polyethylene glycol, alginate and cellulose derivatives could be added to 
improve this formulation [157].  
The development of inhalation formulations accomplished thus far 
will need to be further optimized and subjected to in vivo and clinical studies 
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